Skip to main content

For informational and research purposes only.

Medical DisclaimerTerms of Use

Testosterone Gel: The Definitive Guide

Label and guideline doses, pump presses, when to draw blood, keeping gel off partners and children, TRAVERSE, side effects and what people report.

Testosterone gel at a glance.

Testosterone gel at a glance. Plain testosterone, with no ester, in a quick-drying alcohol gel that is absorbed through the skin. Sold as AndroGel, Testim, Vogelxo and generics in the US, and as Testogel, Irisel, Tostran and Testavan in the UK. Strength 1%, 1.62% or 2%; applied to the skin once daily; only a small share of the testosterone is absorbed (about 10% for AndroGel 1%). The drawing shows the testosterone four-ring skeleton with its 17-beta hydroxyl group and no ester, next to a generic unlabeled metered pump with a small dab of clear gel. Simplified drawing, not a 3D structure. How it works: the alcohol dries in minutes and the outer skin layer acts as a reservoir that releases testosterone over 24 hours; measured points from the AndroGel labels show levels rising within 30 minutes, 8 of 9 men in the normal range by 4 hours after the first 100 mg of 1% gel, a steady daily pattern by day 2 to 3, and a return to baseline 48 to 72 hours after the last dose of AndroGel 1.62%; gel on uncovered skin can pass to partners and children who touch it; the pituitary turns down its signals to the testicles, so they make less testosterone and sperm. Used for men with low testosterone from a testicular or pituitary cause (US labels); not established for age-related low testosterone. Typical labeled dose: AndroGel 1.62%, 40.5 mg (2 pump presses) each morning; 1% gels, 50 mg. How often: once daily, usually in the morning, only on the sites the label names. Status: US Schedule III, UK Class C, Canada Schedule IV, prescription-only in Australia (Schedule 4); US boxed warning on transfer to other people; prohibited in sport at all times under the WADA list. Checked September 2026.

Testosterone gel

Plain testosterone (no ester) in a quick-drying alcohol gel, absorbed through the skin

Sold as AndroGel, Testim, Vogelxo and generics (US) · Testogel, Irisel, Tostran, Testavan (UK)

Testosterone, no ester 1%, 1.62% or 2% On the skin, once daily A small share absorbed

O OH Testosterone no ester attached In a gel metered pump O OH Testosterone no ester attached In a gel
  • Testosteronethe hormone itself, with no ester
  • Gelclear alcohol gel that dries in minutes

Simplified drawing, not a 3D structure. The pump is generic, not a product image.

How it works

Human pharmacology and label data

DAILY USEAFTER STOPPING30 minfirst rise4 h8 of 9 menin normal rangeDay 2–3steady dailypattern48–72 hback tobaseline

Measured points from the AndroGel labels, not to scale; not a prediction for any person.

  1. Skin reservoir

    The alcohol dries in minutes; the outer skin releases testosterone over 24 hours.

  2. Steady within days

    Levels rise within 30 minutes and settle into a daily pattern after 2 to 3 days.

  3. Can rub off

    Gel on uncovered skin can pass to partners and children who touch it.

  4. Own production drops

    The pituitary turns down its signals to the testicles, so they make less testosterone and sperm.

Used for

Men with low testosterone from a testicular or pituitary cause (US labels)

Not established for age-related low testosterone

Typical labeled dose

40.5 mg(2 pump presses) each morning, AndroGel 1.62%

1% gels: 50 mg a day

How often

Once dailyusually in the morning

Only on the sites your label names

Status

  • Controlled: US Schedule III, UK Class C, Canada Schedule IV
  • Prescription-only in Australia (Schedule 4)
  • US boxed warning: transfer to others
  • Sport: prohibited at all times (WADA S1)

Checked Sep 2026

Conceptual summary: the molecule and pump are simplified drawings, not a product image. Absorption figures, doses, status and sport rules come from current labels, guidelines and regulators (checked September 2026).
Published by DoserlyUpdated Next scheduled review: December 202645 min readHow this guide was made
In this guide

What is testosterone gel?

Testosterone gel is a prescription form of testosterone that you rub onto the skin once a day, usually in the morning. It is plain testosterone dissolved in a clear, alcohol-based gel. The alcohol dries within minutes, the outer skin holds the hormone like a reservoir, and testosterone passes into the blood over the next 24 hours. Only a small share of what is applied is absorbed (about 10% for AndroGel 1%); much of the rest stays on the skin for hours, where it can rub off. [1], [2], [3]

The route is called transdermal (absorbed through the skin). Unlike injectable testosterone, gel has no ester, the chemical tail that slows release from an oil depot; the skin itself does the slowing. Gel left on the skin can also pass to anyone who touches it, which is why every US gel label carries a boxed warning. [4], [2]

Gels are labeled for men with hypogonadism (low testosterone from a medical cause): primary hypogonadism, where the testicles fail, or hypogonadotropic hypogonadism, where the brain and pituitary do not send enough signal. US labels still say safety and benefit in "age-related" low testosterone, and under 18, have not been established. AndroGel 1% was the first US testosterone gel, approved on February 28, 2000. [4], [5]

In 2024, Medicare Part D recorded 556,670 fills (including refills) for 132,638 people under its generic "Testosterone" entry, which combines every form and strength of generic plain testosterone, gels included. [6]

ProductWhereStrengthHow the dose is measured
AndroGel 1.62% and generic 1.62% gelsUnited States1.62% (16.2 mg per gram)20.25 mg per pump press; 20.25 mg and 40.5 mg packets
AndroGel 1% and generic 1% gelsUnited States, Canada1% (10 mg per gram)12.5 mg per pump press; 25 mg and 50 mg packets
Testim (and a generic)United States, Canada1%50 mg in a 5 g tube
VogelxoUnited States1%50 mg tube or packet; 12.5 mg per pump press
Testosterone 2% topical solution (generics; the Axiron brand was withdrawn)United States2%30 mg per press, applied to the armpit
Testogel 16.2 mg/g, IriselUnited Kingdom1.62%20.25 mg per pump press; Testogel also in a 40.5 mg sachet
TostranUnited Kingdom2%10 mg per press
TestavanUnited Kingdom, Australia, France2%23 mg per press, with an applicator

[4], [1], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18]

Where each product is sold was checked in September 2026. Canada also sells Taro's 1% gel, and Australia a 1% Testogel (legal status). Testosterone gel is a controlled substance: Schedule III in the United States. Compounded testosterone creams and gels made by pharmacies are different products with no approved label; see compounded testosterone cream. [19]

Conceptual cross-section of skin with a thin drying film of gel on the surface, testosterone gathering in the outer skin layer and passing slowly into small blood vessels. It shows anatomy, not a measured drug effect.
After the alcohol evaporates, testosterone collects in the outer layer of skin, which acts as a reservoir and releases it into small blood vessels over the day. This generated illustration explains anatomy; it is not clinical evidence.

Typical Testosterone Gel Protocols

Transdermal (absorbed through the skin), once a day on the sites each product names · strengths are 1%, 1.62% and 2% (10, 16.2 and 20 mg per gram) · amounts are per daily application; the weekly total is the amount applied, of which about 10% is absorbed, so it cannot be compared with an injection dose · each row is one source's complete schedule [4], [1], [7], [8], [9], [10], [13], [14], [20], [21], [22], [23], [24], [25], [26]
SourceAmount each timeHow oftenWeekly total appliedAdjusted bySource type
US label · AndroGel 1.62% and generics40.5 mg (2 pump presses or one packet)Once daily, morning283.5 mgPre-dose morning level at about 14 and 28 days; 20.25–81 mg, keeping 350–750 ng/dLLabel
US label · AndroGel 1% and generics50 mg (4 pump presses or one packet)Once daily, morning350 mgLevel "at intervals"; up to 100 mgLabel
US label · Testim 1%50 mg (one 5 g tube)Once daily, preferably morning350 mgPre-dose morning level at about 14 days; 100 mg if lowLabel
US label · Vogelxo 1%50 mg (one tube, one packet or 4 pump presses)Once daily, at about the same time350 mgMorning pre-dose level at about 14 days; 100 mg if lowLabel
US label · 2% solution (armpit)60 mg (one press per armpit)Once daily, morning420 mgLevel 2–8 hours after application; 30–120 mgLabel
UK label · Testogel 16.2 mg/g40.5 mg (2 pump presses)Once daily, preferably morning283.5 mgMorning level before application; one-press (20.25 mg) steps, at most 81 mgLabel
The UK Irisel 16.2 mg/g label gives the same schedule
UK label · Tostran 2%60 mg (6 presses)Once daily420 mgLevel 2 hours after application; at most 80 mgLabel
UK label · Testavan 2%23 mg (1 press)Once daily161 mgLevel 2–4 hours after dosing at about days 14 and 35; one-press steps if below 500 or above 1,050 ng/dL; at most 69 mgLabel
The Australian Testavan information gives the same schedule, preferably in the morning
Canadian label · AndroGel 1%50 mg (5 g)Once daily, morning350 mgLevel at intervals; 75 then 100 mg if below 300 ng/dL or response is poorLabel
Canadian label · Testim 1%50 mgOnce daily350 mgMorning level at 7–14 days; at most 100 mgLabel
Australian label · Testogel 1%50 mgOnce daily350 mgMorning level before application; up to 100 mgLabel
Endocrine Society 2018 · 1.62% gel20.25–81 mgOnce daily141.75–567 mgLevel 2–8 hours after application; aim mid-normalGuideline
Also gives 50–100 mg for 1% gel and 40–70 mg for 2% gel
US Veterans Affairs (VA) 2026 · 1.62% gel1–4 pumps (20.25–81 mg)Once daily141.75–567 mgLevel 2–8 hours after application; adjust above 900 ng/dLGuideline
Canadian Urological Association (CUA) 2021 · 1% gel5–10 g (50–100 mg)Once daily350–700 mgAim for 14–17 nmol/LGuideline
Society for Endocrinology (UK) 2022 · Testavan 2%23–46 mgOnce daily161–322 mgLevel 2–6 hours after application; aim mid-normalGuideline
Also gives 20.25–81 mg for the 16.2 mg/g pump and 40–70 mg for Tostran

Every label starts with one application a day, usually in the morning: 40.5 mg of a 1.62% gel, 50 mg of a 1% gel, 60 mg of Tostran 2% gel or the 2% solution, or 23 mg of Testavan 2% gel. The amount is then adjusted in steps using blood tests, within ranges such as 20.25–81 mg for 1.62% gel and 50–100 mg for 1% gel, where the guideline ranges also sit. [4], [1], [7], [9], [13], [14], [23], [26]

Titration Adjusting the dose in steps
The US AndroGel 1.62% and Testim labels adjust by a pre-dose level, drawn in the morning before that day's gel. The 2% products and most guidelines use blood drawn 2 to 8 hours after application instead. Hematocrit can also force a change. [4], [7], [9], [13], [23], [26] See why the draw time matters.
Breaks and cycles
Not applicable. Testosterone replacement is continuous treatment, and no label or guideline describes planned breaks. Levels fall back within days of the last application (what happens when you stop).

Read the units. Gel is measured in pump presses, packets or tubes, not syringe units, and a press means nothing without the product: 20.25 mg from a 1.62% pump, 12.5 mg from a 1% pump, 10 mg from Tostran, 23 mg from Testavan and 30 mg from the 2% solution. So 40.5 mg of AndroGel 1.62% is 2 presses (2.5 g of gel), while 2 presses of a 1% pump is only 25 mg. An 88 g AndroGel pump holds 60 presses, a month at 2 presses a day, after 3 priming presses are discarded. [4], [1], [13], [14], [9]

These are labeled and guideline doses; prescribers adjust them using blood tests and symptoms. The amounts above are for adult men. For women, see testosterone therapy for women, which uses different products and far smaller doses.

Cautions for every schedule above. The US labels rule out testosterone gel with breast cancer or known or suspected prostate cancer, and in pregnant women, because it can harm a female fetus. Gel must be kept off children and partners (how). It can shut down sperm production (fertility), and hematocrit, blood pressure and PSA (prostate-specific antigen, a prostate blood test) need checking (monitoring). [4]

Where schedules differ: blood-test timing, brands and twice-daily use ↓

Where these numbers come from

The US label rows come from the current labels on DailyMed: AndroGel 1.62% (effective October 22, 2025), AndroGel 1% (July 31, 2025), Testim (July 15, 2025), Vogelxo (July 14, 2025) and the Lupin 2% topical solution (January 13, 2026). Generic 1% and 1.62% gels carry the same dosing as their AndroGel reference. The UK rows come from the Testogel 16.2 mg/g summary of product characteristics (text revised January 14, 2025), Irisel (June 18, 2026), Tostran (May 8, 2026) and Testavan (August 21, 2023); the Australian Testavan information (April 22, 2026) gives the same schedule. The Canadian rows come from the AndroGel 1% monograph (August 2025) and the Testim monograph (January 16, 2026), and the Australian Testogel row from its product information (October 7, 2025). Weekly totals are the daily amount times seven; the labels do not state them. [4], [1], [7], [8], [9], [27], [10], [12], [13], [14], [15], [20], [21], [22]

The guideline rows each come from one document: the Endocrine Society guideline (2018), the VA's January 2026 recommendations (Table 3), the Canadian Urological Association guideline (2021) and the Society for Endocrinology guideline (2022, Table 2). Rows never mix strengths, so each guideline's ranges for other strengths are given in the row notes. [23], [24], [25], [26]

Not used for any row: clinic protocol sources (no peer-reviewed practice paper or published clinic protocol with a complete gel schedule different from the labels was found; gels are prescribed to label), twice-daily or split applications and sites the labels do not name (discussed only in community reports), the Australian AndroForte 5 cream (a cream, covered in compounded testosterone cream), and the discontinued Fortesta 2% gel (no longer sold).

Open the searchable source directory

What is testosterone gel commonly used for?

Its approved use is replacing testosterone in men whose bodies cannot make enough because of a medical condition: testicular failure (for example from undescended testicles, removal, chemotherapy or Klinefelter syndrome) or a missing signal from the brain or pituitary (from a hormone deficiency, a tumor, injury or radiation). [4]

Some guidelines prefer gel to start. The European Association of Urology (EAU) suggests gel rather than a long-acting injection when starting treatment in men at high risk (unlike a depot, gel clears within days of stopping), and the European Academy of Andrology, for men with functional low testosterone (from causes such as obesity or illness rather than damage to the testicles or pituitary), puts exercise and weight loss first and suggests a transdermal preparation if testosterone is started. A 2020 American College of Physicians guideline, now listed as inactive, instead suggested injections for age-related low testosterone because they cost less. [28], [4], [29], [30]

What does testosterone gel improve?

  • Sexual function and mood. In the AndroGel 1% approval trial of 227 men, sexual function and mood improved by day 30. In TRAVERSE, men with low sex drive had about 0.5 more sexual acts a day than on placebo, with more desire, but erections did not improve. In the Testosterone Trials of men 65 and older, a year of 1% gel improved sexual function and mood a little. It did not improve energy (vitality), and walking improved only slightly when all the men were counted, not in the men chosen for walking problems. [31], [32], [33]
  • Muscle and fat. In the same AndroGel trial, lean mass rose 2.74 kg on 100 mg and 1.28 kg on 50 mg after 90 days, while fat fell by about 1 kg. In the Testim approval trial, lean mass rose 1.7 kg over 90 days on 100 mg a day, significantly more than on a patch or placebo. [31], [34]
  • Bone and red blood cells. In men followed for up to 42 months on AndroGel, spine bone density rose. In TRAVERSE, anemia was corrected in 45.0% of men on testosterone vs 33.9% on placebo after a year. [35], [36]

These are average effects in trials; see the evidence and the results timeline guide.

How long does testosterone gel take to work?

Blood levels move fast; symptoms move slowly. With AndroGel 1% 100 mg, testosterone rose within 30 minutes of the first application and was in the normal range in 8 of 9 men by 4 hours, and levels settle into a steady daily pattern after 2 to 3 days. In the AndroGel 1% trial, sexual function and mood had improved as much as they would by day 30, while the Canadian Urological Association tells men to expect changes in sex drive, energy and sexual function after 3 months or longer. [1], [37], [31], [25]

Where do testosterone gel protocols differ?

Each label is clear about its starting dose. The disagreements are about when to draw blood, what level to aim for and whether one brand can replace another.

When should blood be drawn on testosterone gel?

It depends on the product and the guideline. Gel levels rise in the hours after each application, so a sample 2 hours after the gel and one just before the next dose describe the same dose at different moments. [4], [23]

SourceWhen to draw on gelTarget
AndroGel 1.62% label (US)Morning, before that day's gel, at about 14 and 28 days350–750 ng/dL (about 12–26 nmol/L)
2% topical solution label (US)2–8 hours after application300–1,050 ng/dL
Tostran label (UK)2 hours after application, at about day 145.0–15.0 µg/L (about 500–1,500 ng/dL)
Testavan label (UK, Australia)2–4 hours after dosing, at about days 14 and 3517.3–36.4 nmol/L (500–1,050 ng/dL)
Endocrine Society 2018, VA 20262–8 hours after application, after at least a weekMid-normal range
American Urological Association (AUA) 2018First check 2–4 weeks after starting, with gel applied on the test day450–600 ng/dL (about 16–21 nmol/L)
Society for Endocrinology (UK) 20222–6 hours after application, 2–3 weeks after a changeMid-normal range
British Society for Sexual Medicine 20232–4 hours after application15–30 nmol/L (about 430–865 ng/dL)

[4], [9], [13], [14], [23], [24], [38], [26], [39]

The pattern: the US 1.62% gel and Testim labels judge the dose by the lowest point of the day, while the 2% products and most guidelines judge it closer to the peak. The numbers are not comparable, so writing down the hour of the last application next to each result matters. [7], [13], [4]

Draw blood from an arm without gel. Gel where the needle goes in can make a result falsely high. In one hospital's records of 578 gel users, 48 had a result above 1,000 ng/dL, and gel on the draw site was the likely cause in 7. In another study, blood from the gel arm read 33.2 nmol/L against 14.2 nmol/L from the other arm. UK guidelines say to avoid the application site. [40], [41], [26], [39]

Is one gel brand the same as another?

No. The US labels say the application site and dose "are not substitutable with other topical testosterone products". Formulations differ, and so does how much gets through the skin. [4]

  • Testim versus AndroGel 1%. In 29 men given one 50 mg dose of each, Testim produced 30% higher total testosterone exposure and 47% higher free testosterone; the two were not bioequivalent. [42], [43]
  • Pharmacy substitution. FDA rates AndroGel 1% and its generics as one group (AB1) and Testim, its generic and the Vogelxo packet as another (AB2); a pharmacy can swap only within a group. [5]
  • Switching after a poor response. In 75 men who switched brands because their levels stayed low, moving from AndroGel to Testim raised average testosterone from 311 to 484 ng/dL; moving the other way did not. The AUA calls switching to another topical product a reasonable option. [44], [38]

A brand change is a dose change, so it usually means a new blood test.

Is one application a day enough, or should it be split?

Every label and guideline gives one daily application, mostly in the morning. No trial has tested twice-daily or split applications of an approved gel, so no source gives a split schedule; some people report a dip before the next dose (community). On gel, the average daily curve is fairly flat, but each man's peak arrives at a different time of day, one reason single results vary. [4], [23], [45]

What happens when you stop testosterone gel?

The gel leaves quickly; your own hormone production takes much longer to return.

  • The gel itself. Testosterone returns to about where it started within 48–72 hours of the last AndroGel 1.62% dose, and by the fifth day after AndroGel 1%; UK Testogel gives 72–96 hours. [4], [1], [10]
  • Your own testosterone. Gel turns down the pituitary's two signals to the testicles, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), in proportion to the testosterone it adds. Recovery depends on the original cause and how long treatment lasted; in men with a lasting cause, low testosterone returns. No study has tracked recovery after long-term gel specifically. [2]
  • Sperm. In contraceptive trials of healthy men given testosterone-based regimens, sperm counts returned to 20 million per mL in 67% within 6 months, 90% within 12 months and 100% within 24 months. [46]

See stopping TRT for the full picture.

How does testosterone gel compare with other forms?

Gel gives a fairly flat average daily level and clears within days, and the Endocrine Society says high hematocrit is less common on gel than on injections (a pooled analysis of trials could not show a clear gap). But it is a daily task, its absorption varies from man to man, and it can transfer to other people. [45], [23], [47], [4]

How much gel gets into the body?

About 10% of the testosterone in AndroGel 1% is absorbed; one early study measured 9–14%, the UK Tostran information gives about 12% and the UK Testogel 16.2 mg/g information 1% to 8.5%. Absorption varies between men, which is why labels adjust the dose by blood tests. [1], [2], [13], [10]

With the 2% gel, 79.1%, 79.5% and 73.8% of men reached the normal range from the lightest to the heaviest third, and heavier men were on higher doses; the AndroGel 1% trial found no difference by body mass index. [48], [1]

Diverging horizontal bars showing how much each factor changed measured blood testosterone (exposure or average level) after gel, against each study's own comparison. Where it goes on: Abdomen instead of upper arms and shoulders, −30 to −40% (AndroGel 1.62%, 81 mg, 36 men, total exposure (AUC), Miller 2011); Testavan on the abdomen, −33% (vs upper arm and shoulder, average 372 vs 557 ng/dL, UK information); Testavan on the thigh, −29% (vs upper arm and shoulder, average 395 vs 557 ng/dL). Showering after applying: Shower 15 minutes after, −68% (50 mg gel, 10 transgender men, average 320 vs 994 ng/dL, de Ronde 2011); Shower 30 minutes after, −60% (same small study, average 401 vs 994 ng/dL); Shower 2 hours after, −13% (AndroGel 1.62%, 81 mg, 24 men, average level (Cavg)); Shower 6 hours after, −12% (same study); Shower 10 hours after, no change (same study). Other products on the skin: Antiperspirant 2 minutes before, up to −33% (2% solution, 30 mg in the armpit, healthy women, total exposure (AUC)); Sunscreen 1 hour after, +8% (AndroGel 1.62%, 40.5 mg, 18 men, average level (Cavg)); Moisturizer 1 hour after, +14% (same study). Wait your product's full washing time and use only its label sites. Sunscreen or moisturizer an hour later raised levels only slightly.

What changes blood testosterone from gel

Change in measured blood testosterone (exposure or average level), against each study's own comparison. Bars to the left of the line mean lower; to the right, higher.

Where it goes on

Abdomen instead of upper arms and shoulders: −30 to −40%
AndroGel 1.62%, 81 mg, 36 men · total exposure (AUC) · Miller 2011
Testavan on the abdomen: −33%
vs upper arm and shoulder · average 372 vs 557 ng/dL · UK information
Testavan on the thigh: −29%
vs upper arm and shoulder · average 395 vs 557 ng/dL

Showering after applying

Shower 15 minutes after: −68%
50 mg gel, 10 transgender men · average 320 vs 994 ng/dL · de Ronde 2011
Shower 30 minutes after: −60%
same small study · average 401 vs 994 ng/dL
Shower 2 hours after: −13%
AndroGel 1.62%, 81 mg, 24 men · average level (Cavg)
Shower 6 hours after: −12%
same study
Shower 10 hours after: no change
same study

Other products on the skin

Antiperspirant 2 minutes before: up to −33%
2% solution, 30 mg in the armpit, healthy women · total exposure (AUC)
Sunscreen 1 hour after: +8%
AndroGel 1.62%, 40.5 mg, 18 men · average level (Cavg)
Moisturizer 1 hour after: +14%
same study

Wait your product's full washing time and use only its label sites. Sunscreen or moisturizer an hour later raised levels only slightly.

How application site, early washing, moisturizer, sunscreen and antiperspirant changed measured blood testosterone (exposure or average level) in label and pharmacokinetic studies. Each bar is one study's measured change against that study's own comparison; the studies used different products and doses. Sources: AndroGel 1.62% US label · Miller 2011 · de Ronde 2011 · Testosterone 2% solution US label · Testavan UK SmPC.

Where can testosterone gel be applied?

On clean, dry, intact skin, and only where your product's label says, because the site changes both absorption and transfer. [4], [37]

ProductWhere the label says to apply it
AndroGel 1.62% and genericsShoulders and upper arms only, within the area a short-sleeved T-shirt covers; not the abdomen, genitals, chest, armpits or knees
AndroGel 1% and genericsShoulders, upper arms and/or abdomen; not the genitals, chest, armpits, knees or back
TestimShoulders and/or upper arms; not the abdomen or genitals
2% topical solutionArmpits only, with the applicator
Testogel 16.2 mg/g (UK)Shoulders and upper arms; not the genitals
Tostran (UK)Abdomen or both inner thighs, rotating daily
Testavan (UK, Australia)Upper arm and shoulder, with the applicator; the abdomen and thigh deliver less

[4], [1], [7], [9], [10], [13], [14]

  • Abdomen and legs. AndroGel 1.62% on the abdomen alone gave about 30–40% lower exposure than on the upper arms and shoulders. With Testim, levels were highest from the shoulders and arms and lowest from the legs, and Testavan on the abdomen or thigh averaged 372 and 395 ng/dL against 557 ng/dL on the arm and shoulder. [37], [49], [14]
  • Scrotum. No US or UK gel is labeled for genital skin. Scrotal skin absorbs far more: 25 mg of cream there kept testosterone in the normal range for 16 hours, and the only approved scrotal product among those reviewed is AndroForte 5, a cream sold in Australia (compounded testosterone cream). [50], [51], [52]

How long should you wait before showering, swimming or using lotion?

Follow your product's wait: at least 2 hours for AndroGel 1.62%, Testim, Vogelxo, the 2% solution, Tostran and UK Testavan (1–2 hours for Australian Testavan); 5 hours for AndroGel 1% and its generics; 1 hour for UK Testogel. The UK Society for Endocrinology advises 6 hours. [4], [1], [50], [7], [8], [9], [10], [13], [14], [26]

  • Very early washing matters. In one small study in transgender men, showering 15 or 30 minutes after a 50 mg gel lowered average testosterone from 994 to 320 and 401 ng/dL. [53]
  • Washing after the wait matters little. Showering 2 or 6 hours after AndroGel 1.62% lowered average exposure by 13% and 12%; at 10 hours it made no difference. [4], [54]
  • Moisturizer and sunscreen. Applied an hour after AndroGel 1.62%, moisturizer raised average exposure by 14% and sunscreen by 8%; the UK Testogel information says neither reduces efficacy. [27], [10]
  • Antiperspirant. With the underarm solution, antiperspirant goes on at least 2 minutes before; in a study it lowered exposure by up to 33%. [9]
  • Exercise and sweat. No study has measured the effect of exercise or sweating after application.

Alcohol gels are flammable until dry, so avoid fire, flames and smoking until the gel has dried. [4]

AndroGel 1% and 1.62%

AndroGel is the original US testosterone gel: AndroGel 1% was approved on February 28, 2000 and AndroGel 1.62% on April 29, 2011. The two strengths are dosed differently. [5], [4]

  • AndroGel 1.62%: 20.25 mg per press, starting at 40.5 mg each morning on the shoulders and upper arms only. In its approval trial of 274 men, 81.6% (146 of 179) had average levels in the normal range at day 112, and 11.2% had a peak above 1,500 ng/dL. It is the gel used in TRAVERSE. [4], [55]
  • AndroGel 1%: 12.5 mg per press, starting at 50 mg, adjustable to 75 or 100 mg; it may also go on the abdomen and needs a 5-hour wait before showering. In its approval trial, 87% of 129 titrated men had average levels in range at day 180. [1]

Generic 1% and 1.62% gels are rated equivalent to the matching AndroGel. Canada sells AndroGel only as the 1% gel; France sells a 16.2 mg/g AndroGel. [5], [16], [17]

Testim and Vogelxo

Testim is a 1% gel in single-use 5 g tubes (50 mg), approved in the United States on October 31, 2002, and also sold in Canada. It goes on the shoulders and upper arms, never the abdomen, and may have an alcoholic or musk odor. In its label studies, 74% of 192 titrated men were in range at day 90, and it delivered about 30% more testosterone than AndroGel for the same 50 mg. Vogelxo (approved June 4, 2014) is a 1% gel in tubes, packets or a pump; its packet is rated equivalent to Testim. [5], [7], [21], [42], [8]

The 2% underarm solution

A liquid rather than a gel: 30 mg per press, applied with an applicator cup to each armpit (60 mg a day to start, 30–120 mg), and judged by blood drawn 2–8 hours later. In its label trial, 84.1% of men were in range at day 120. The brand, Axiron (approved November 23, 2010), was withdrawn on July 23, 2018, not for safety reasons; generics remain. [9], [5], [56]

Testogel, Irisel, Tostran and Testavan (UK, Europe and Australia)

  • Testogel 16.2 mg/g (UK): 40.5 mg a day from a pump or sachet, up to 81 mg. The UK 1% sachet is marked discontinued; Australia still has Testogel 1%. Irisel, another 16.2 mg/g gel in a pump, was first authorised in the UK on June 18, 2026. [10], [11], [57], [22], [12]
  • Tostran 2% (UK): 10 mg per press, 60 mg a day on the abdomen or inner thighs, judged 2 hours after application. It is the same strength as the discontinued US Fortesta. [13]
  • Testavan 2% (UK, Australia, France): 23 mg per press, spread with an applicator, from one to three presses. Ireland markets a 20 mg/g gel as Testarzon. [14], [15], [18], [58]

Fortesta: no longer sold in the US

Fortesta was a 2% gel for the front and inner thighs: 40 mg (4 presses) a day, adjustable from 10 to 70 mg, judged by blood drawn 2 hours after application. In its approval trial, 77.5% of men (100 of 129) were in range; skin reactions occurred in 16.1%. The brand was discontinued after a December 1, 2023 sponsor letter, not for safety reasons, and marketing of its only generic ended on January 31, 2026, so no 2% gel is sold in the United States (checked September 2026). Tostran is the nearest UK equivalent. [59], [60], [61], [62], [13]

Androderm patch: no longer sold

Androderm, approved on September 29, 1995, was a patch worn from night to night on the back, abdomen, upper arms or thighs: 4 mg/day to start, adjusted between 2 and 6 mg/day by an early-morning level, with 7 days before reusing a site. It copied the body's natural daily rhythm, but skin reactions affected 28% of men with the newer patches and 48% with older ones, and it had to come off before a magnetic resonance imaging (MRI) scan. It transferred far less testosterone to clothing than gel. It is no longer marketed in the United States (FDA found this was not for safety reasons) and was cancelled in Canada in 2021–22 (checked September 2026). [63], [64], [65], [66], [16]

Striant buccal system: no longer sold

Striant was a small tablet-like patch held on the gum above an incisor tooth, where testosterone passed through the lining of the mouth (buccal): 30 mg twice daily, about 12 hours apart. In its label trial, 86.6% of men were in range; gum or mouth irritation affected 9.2%, and levels fell below normal within 2 to 4 hours of removal. FDA withdrew its approval effective June 15, 2020, in a notice covering 16 applications, and no buccal testosterone is sold in the United States (checked September 2026). [67], [68], [69]

How should testosterone gel be stored?

Store it at room temperature, away from flames and out of reach of children and pets. Each product's label sets its own range. [4], [7]

ProductStorage
AndroGel 1.62%20–25 °C (short spells at 15–30 °C allowed)
AndroGel 1%25 °C (short spells at 15–30 °C allowed)
Testim, Vogelxo20–25 °C
2% topical solution25 °C, upright
Testogel 16.2 mg/g (UK)No special storage conditions
Irisel (UK)Do not store above 25 °C
Tostran (UK)Do not store above 25 °C; do not refrigerate or freeze; once opened, keep the canister upright
Testavan (UK)No special storage conditions
Testogel 1% (Australia)Below 25 °C
Testavan (Australia)Below 25 °C in the original package; use within 60 days of opening

[4], [1], [7], [8], [9], [10], [12], [13], [14], [22], [15]

The AndroGel labels give no separate time limit once a pump is opened. Used packets, tubes and pumps go in household trash where a child or pet cannot reach them. [4], [1], [7]

For carrying gel on a trip, see traveling with testosterone.

How can you keep testosterone gel off partners, children and pets?

Wash your hands with soap and water right after applying, let the gel dry, cover the site with clothing such as a T-shirt, and wash the site before skin-to-skin contact. Together, those steps prevented almost all transfer in the label studies. [4], [70]

Conceptual illustration in two panels: testosterone particles passing between two touching skin surfaces, and a fabric layer between the surfaces stopping them. No people are shown.
Gel on uncovered skin can pass to anyone who touches it; a layer of clothing over the dried site blocks most of that transfer. This generated illustration explains a concept; it is not clinical evidence.

Why is there a boxed warning?

Children have been harmed by touching a parent's gel. The labels describe children who developed an enlarged penis or clitoris, pubic hair, more erections and sex drive, aggressive behavior and bones that matured too fast. Most signs went away once the exposure stopped, but in a few, enlarged genitals did not fully return to normal size and bone age stayed ahead of the child's age. In some cases the precautions had not been followed. [4]

FDA announced the boxed warning on May 7, 2009, and it appeared in AndroGel's label that September. An FDA review counted 30 reports of secondary exposure with harm in children and adults between 2001 and 2009. The UK regulator repeated the warning in January 2023 after a UK report of a child with faster growth and genital enlargement from a parent's gel. In one published series, all 5 children exposed to a relative's gel were moderately to severely virilized; in another, the parents did not know their gel was the cause. [71], [72], [70], [73], [74]

Adult women can be affected too, with more body or facial hair, acne, a deeper voice or menstrual changes. Gel is contraindicated in pregnancy because testosterone can masculinize a female fetus. [75], [70], [4]

How much gel transfers, and what stops it?

The label studies used intense contact: a woman rubbing the man's application site for 15 minutes, hours after he applied the gel.

  • Skin to skin. Two hours after 81 mg of AndroGel 1.62%, direct contact raised women's average testosterone by 280%. With AndroGel 1%, every unprotected partner in a 38-couple study reached more than twice her starting level. [4], [1]
  • A T-shirt. With a T-shirt over the dried AndroGel 1.62% site, women's levels rose only 6%; with AndroGel 1%, a shirt prevented transfer completely. Clothing works best over the arms and shoulders: over 1.62% gel on the abdomen, an unapproved site, levels still rose 43–60%. [4], [1], [76]
  • Washing the site. Washing the application site before contact brought partners' levels back to baseline. Without it, transfer was still seen at least 12 hours after application. [77], [76]
  • Hands and clothing. Washing hands removed 96–99% of the residue. T-shirts worn over gel held a median 6,763 micrograms of testosterone, against 25 micrograms over a patch, and the 1% generic labels note a possible case of transfer through towels and sheets. [4], [8], [65], [50]
Horizontal bars showing the rise in a female partner's testosterone after 15 minutes of rubbing the man's application site. AndroGel 1.62%, 81 mg on shoulders and upper arms: skin to skin +280%, with a T-shirt +6% (average level). AndroGel 1.62% on the abdomen, not an approved site, with a T-shirt: +43% on day 1 to +60% on day 7. Testosterone 2% solution, 120 mg in the armpits, with a T-shirt: +13% (total exposure). Measured differently: AndroGel 1%, 100 mg, 38 couples: every unprotected partner rose above 2 times her starting level; a shirt prevented transfer completely. Vogelxo 1%, 50 mg, 48 couples: unprotected total exposure 2.8 times her starting level; a shirt or washing the site kept the rise under 10%. Washing hands removed 96 to 99% of the gel left on them; an unwashed site still transferred at least 12 hours after applying; washing the site before contact brought partners back to baseline. Wash hands, cover the dried site, and wash it before skin contact. The label studies used 15 minutes of deliberate rubbing.

Gel on a partner's skin: how much transfers, and what stops it

Rise in a female partner's testosterone after 15 minutes of rubbing the man's application site.

Skin to skinSite covered by a T-shirt

AndroGel 1.62%, 81 mg on shoulders and upper arms
Skin to skin +280%; with a T-shirt +6%. Contact 2 hours after applying, 8 and 12 couples, average level (Cavg).
AndroGel 1.62% on the abdomen (not an approved site)
With a T-shirt +43% (day 1) to +60% (day 7). T-shirt over the site, 16 couples, average level (Cavg).
Testosterone 2% solution, 120 mg in the armpits
With a T-shirt +13%. T-shirt over the site, 10 couples, total exposure (AUC).

Measured differently, so not on the scale

AndroGel 1%, 100 mg
Skin to skin: every partner rose above 2 times her starting level at some point. A shirt prevented transfer completely. 38 couples, daily contact 2–12 hours after applying.
Vogelxo 1%, 50 mg
Skin to skin: total exposure (AUC) 2.8 times her starting level. Shirt or washing the site: under 10% rise. 48 couples, contact 2 hours after applying.

What else the studies found

Washing hands
Removed 96–99% of the gel left on them.
Unwashed site
Still transferred at least 12 hours after applying.
Washing the site
Before contact brought partners back to baseline.

Wash hands, cover the dried site, and wash it before skin contact. The label studies used 15 minutes of deliberate rubbing.

Rise in a female partner's testosterone after 15 minutes of rubbing the man's application site, by product and protection, from the label transfer studies. The contact was deliberately intense, and each bar comes from a separate study. Sources: AndroGel 1.62% US label · AndroGel 1% US label · Vogelxo US label · Testosterone 2% solution US label.

What about pets?

The US labels say to dispose of used gel where pets cannot reach it, and the UK Irisel information says to cover the site to prevent transfer to other people "as well as pets". No study of pets exposed to human testosterone gel was found; keeping them off the site and off clothes worn over it follows the same logic as for children. [7], [12]

What should you do if someone is exposed?

Wash the area of contact on the other person with soap and water as soon as possible. If a child develops genital growth or pubic hair, or a woman develops new hair growth or acne, tell a doctor that someone in the home uses testosterone gel; the labels say to stop the gel until the cause is found. [4]

What does testosterone gel do to fertility, estrogen and red blood cells?

Each has its own guide; here is what is specific to gel.

Fertility. Gel lowers LH and FSH in proportion to the testosterone it adds, and the labels warn it may lower sperm counts, possibly to zero (azoospermia). In a contraception trial in healthy men, gel alone brought sperm to 1 million per mL or fewer in 23%: not a contraceptive, but a real suppression. The AUA says testosterone should not be prescribed to men trying to conceive, and the US male infertility guideline extends that to men interested in future fertility. See TRT and fertility. [2], [4], [78], [38], [79]

Estrogen and DHT. Some testosterone is converted to estradiol: on AndroGel 1%, estradiol rose within 30 days but stayed in the normal male range, and no guideline sets a routine estradiol target. Skin contains the enzyme 5-alpha reductase, so gel raises dihydrotestosterone (DHT) more than a patch: 3.6- to 4.6-fold against 1.3-fold. No study has linked gel's higher DHT to hair loss or prostate outcomes. See estrogen on TRT. [1], [2], [45], [38]

Red blood cells. In a network meta-analysis of 29 randomized trials, hematocrit rose about 3.0 percentage points more than placebo on gel, against 4.0 on enanthate or cypionate injections and 1.6 on long-acting undecanoate injections; only the difference between injections and patches was clear. In observational studies, hematocrit went above 50% in 12.8% of gel users vs 66.7% of injection users in one clinic, and in 25 of 498 gel users vs 69 of 304 on long-acting injections in one center's registry. US gel labels ask for hematocrit before treatment, 3–6 months after starting and then yearly. See hematocrit on TRT. [47], [80], [81], [4]

What do we actually know about testosterone gel in people?

That gel raises testosterone into the normal range in most men is settled; it is how gels were approved. What makes gel unusual is that the two biggest long-term testosterone trials, the Testosterone Trials and TRAVERSE, both used gels, so much of the long-term safety evidence for testosterone is gel evidence. [33], [82]

Conceptual comparison of cells in a laboratory dish, an animal study notebook, and human study records. Each answers a different research question.
Cell and animal studies explore how a medicine might work; human studies test what happens in people. Testosterone gel's approval rests on human hormone studies, and its long-term safety picture comes from large randomized trials in people.

Which studies used testosterone gel itself?

StudyWho and whatWhat it foundWhat it cannot show
AndroGel 1% trial (Wang 2000, controlled trial)227 men; 1% gel or a patch, 180 daysSexual function and mood better by day 30; lean mass up to 2.74 kgComparison with placebo or injections [31]
AndroGel follow-up (Wang 2004)163 men, up to 42 monthsBenefits kept; spine bone density rose; 3 prostate cancers found after PSA risesCause and effect; no placebo [35]
Testim trial (Steidle 2003)406 men; Testim, a patch or placebo, 90 daysLean mass up 1.7 kg on 100 mg; erections and desire better than placeboLong-term outcomes [34]
AndroGel 1.62% trial (Kaufman 2011, 2012)274 men; gel or placebo for 182 days, then open-label to a year81.6% in range at day 112, against 28.6–37.0% on placebo across the study visits; 77.9% at a yearOutcomes beyond hormone levels [55], [83]
Testosterone Trials (Snyder 2016)790 men aged 65 or older; 1% gel or placebo, 1 yearSmall gains in sexual function and mood; no gain in energy or walking in the physical function trialLong-term safety [33]
TRAVERSE (Lincoff 2023)5,204 men aged 45–80 at high heart risk; 1.62% gel or placebo, mean 21.7 monthsHeart attack, stroke or heart death in 7.0% vs 7.3%, within the trial's safety margin; more atrial fibrillation, acute kidney injury and lung clots; more fracturesInjections; low-risk men; more than about 2 years of use (about 61% stopped the gel early) [82], [4]

Across the approval trials, 74–87% of men reached the normal range, so between about 1 in 8 and 1 in 4 did not at a given check, even with titration. [38]

Is gel as effective as injections?

No randomized trial has compared gel with injections on symptoms or long-term outcomes; a 2022 systematic review found hardly any direct comparisons. Both forms reach the normal range in most men, the Endocrine Society says high hematocrit is more common on injections (a pooled analysis of trials could not show a clear gap between gel and injections), and many men stop gel: in US claims data, of 15,435 men who started a topical product, 34.7% had kept filling it without a gap of more than 30 days at 6 months, and 15.4% at a year, though about half of those who stopped later restarted (the study did not include injection users). [84], [23], [47], [85]

How does testosterone gel work?

The gel is hydroalcoholic (made with alcohol and water). The alcohol carries testosterone into the outer skin and evaporates within minutes; a 2% gel dried in a median of 2.4 minutes. The skin then acts as a reservoir, releasing testosterone into small blood vessels for the rest of the day. That reservoir, not testosterone's own short life in the blood (10 to 100 minutes), sets the once-a-day schedule. [1], [86], [4]

In the blood, it acts like the body's own testosterone: about 40% is bound to sex hormone-binding globulin (SHBG), about 2% is free, and tissues convert some to DHT and estradiol. [4]

Why it switches off your own production. The brain senses testosterone from any source. When levels rise, the pituitary lowers its LH and FSH signals to the testicles, which then make less testosterone and fewer sperm. [2], [4]

What are the risks and unanswered questions?

Is testosterone gel safe?

For men with a confirmed diagnosis who follow the application rules and get regular blood tests, it is a standard, well-studied treatment with known risks: transfer to others, a rise in red blood cells, blood clots, higher blood pressure, prostate effects and loss of fertility. It has the best long-term heart-safety data of any form, because TRAVERSE tested it; safety beyond about two years remains less certain. [4], [82]

What side effects do the labels list?

In the 182-day AndroGel 1.62% trial, the reactions more common than on placebo were a rise in PSA (11.1%), emotional lability such as mood swings, impatience or anger (2.6%), high blood pressure (2.1%), a rise in hematocrit or hemoglobin (2.1%) and skin inflammation, mostly away from the application site (2.1%). Application-site reactions occurred in 0.9% of men (2 of 234). About 10.7% stopped because of side effects, most often a rising PSA. [4]

Skin reactions vary by product. The AUA gives 3–16% across topical products, the Fortesta trial found 16.1%, and in the AndroGel 1% trial skin irritation affected 5.5% of men on gel against 66% on a patch. The labels also list acne, breast enlargement (gynecomastia), fluid retention, sleep apnea and changes in cholesterol. [38], [59], [31], [4]

Does testosterone gel affect the heart?

The best evidence comes from TRAVERSE, a randomized trial of about 5,200 men aged 45 to 80 with heart disease or high heart risk, given daily AndroGel 1.62% or a placebo gel; the average dose was 65 mg a day. Among the 2,596 men who used testosterone gel and the 2,602 who used placebo gel, it found: [82], [4]

  • Heart attack, stroke or heart death: 182 men (7.0%) on testosterone vs 190 (7.3%) on placebo; hazard ratio 0.96, with a 95% confidence interval of 0.78 to 1.17. The top of that range stayed below the trial's safety margin of 1.5, so a large rise in risk was ruled out. [82], [4]
  • Heart rhythm: atrial fibrillation 3.5% vs 2.4%; nonfatal rhythm problems needing treatment 5.2% vs 3.3%. [4]
  • Kidneys: acute kidney injury 2.3% vs 1.5%. [4]
  • Clots: venous clots 1.7% vs 1.2%, including pulmonary embolism 0.9% vs 0.5%. [4]
  • Fractures: 91 of 2,601 men (3.50%) vs 64 of 2,603 (2.46%), counting every randomized man. [87]
  • Blood pressure: systolic pressure rose 1.0 mm Hg on testosterone and fell 0.5 mm Hg on placebo by 36 months. [4]
  • Substudies: testosterone increased sexual activity and desire but not erections in men with low libido; it did not significantly slow progression from prediabetes to diabetes; mood and energy improved slightly more than on placebo, both in the 2,643 men with significant depressive symptoms and in the whole trial, but in the 49 men with persistent depressive disorder there was no clear difference, though that group was too small for a firm answer. [32], [88], [89]
Paired horizontal bars showing the percent of men with each outcome in TRAVERSE, 2,596 men on testosterone gel vs 2,602 on placebo gel. Heart attack, stroke or heart death: 7.0% vs 7.3% (182 vs 190 men; hazard ratio 0.96, 95% CI 0.78–1.17; met the 1.5 safety margin); Nonfatal rhythm problems needing treatment: 5.2% vs 3.3%; Atrial fibrillation: 3.5% vs 2.4%; Clinical fracture: 3.5% vs 2.5% (91 of 2,601 vs 64 of 2,603 in the full analysis set); Acute kidney injury: 2.3% vs 1.5%; Venous clots (all): 1.7% vs 1.2%; Pulmonary embolism: 0.9% vs 0.5%. About 5,200 men aged 45–80 at high heart risk; daily gel; mean treatment 21.7 months; about 61% stopped their study gel. Not a trial of injections.

TRAVERSE: absolute results

Testosterone gel (2,596 men)Placebo gel (2,602 men)

Heart attack, stroke or heart death
Testosterone 7.0% vs placebo 7.3% (182 vs 190 men; hazard ratio 0.96, 95% CI 0.78–1.17; met the 1.5 safety margin)
Nonfatal rhythm problems needing treatment
Testosterone 5.2% vs placebo 3.3%
Atrial fibrillation
Testosterone 3.5% vs placebo 2.4%
Clinical fracture
Testosterone 3.5% vs placebo 2.5% (91 of 2,601 vs 64 of 2,603 in the full analysis set)
Acute kidney injury
Testosterone 2.3% vs placebo 1.5%
Venous clots (all)
Testosterone 1.7% vs placebo 1.2%
Pulmonary embolism
Testosterone 0.9% vs placebo 0.5%

About 5,200 men aged 45–80 at high heart risk; daily gel; mean treatment 21.7 months; about 61% stopped their study gel. Not a trial of injections.

TRAVERSE results as absolute percentages of men, AndroGel 1.62% vs placebo gel. The trial tested this gel in men at high heart risk. Sources: Lincoff 2023 (TRAVERSE) · AndroGel 1.62% US label (TRAVERSE results) · Snyder 2024 (fractures).

Its limits. The average man used the gel for 21.7 months, about 61% stopped their study gel early, and everyone enrolled was at high heart risk, so it cannot speak to longer use or to lower-risk men. [82], [4]

Blood pressure. In a 16-week study with 24-hour monitoring, AndroGel 1.62% raised average blood pressure by 1.9/1.3 mm Hg, and by 3.0/2.2 mm Hg in men already treated for high blood pressure. Labels advise against gel with uncontrolled high blood pressure. [4], [90]

Gel compared with injections. In a study of 544,115 men starting testosterone in two US insurance databases and UK general-practice records, those starting injections had more heart attacks, unstable angina or strokes in their first year than those starting gel (hazard ratio 1.26, 95% confidence interval 1.18 to 1.35). It was observational, did not check whether the men needed testosterone and cannot prove cause. [91]

The AndroGel and Testim labels have carried the TRAVERSE results since July 2025, though the current Vogelxo and 2% solution labels did not yet include them; on every US gel label, the only boxed warning is about secondary exposure (checked September 2026). See TRT and heart health. [92], [4], [7], [8], [9]

What about blood clots, sleep apnea and fluid retention?

  • Blood clots. Clots in the legs (deep vein thrombosis) and lungs (pulmonary embolism) have been reported with testosterone products; leg pain, swelling, warmth or redness, or sudden shortness of breath need urgent assessment. [4]
  • Sleep apnea. Testosterone may worsen sleep apnea, especially with obesity or chronic lung disease. [4]
  • Fluid retention. Swelling, with or without heart failure, can be serious in people with heart, kidney or liver disease. [4]

Could testosterone gel affect the prostate?

Testosterone can enlarge the prostate and raise PSA. In the AndroGel 1.62% trial, PSA rose by an average of 0.14 ng/mL over six months, against a fall of 0.12 ng/mL on placebo. In TRAVERSE, which excluded men with a PSA above 3.0 ng/mL, high-grade prostate cancer occurred in 5 of 2,596 men on testosterone (0.19%) vs 3 of 2,602 on placebo (0.12%), a difference that was not significant. US labels contraindicate gel in known or suspected prostate cancer and warn that men with an enlarged prostate may get worse urinary symptoms. See TRT and the prostate. [4], [93]

Checked September 2026. Rules differ by country and change often.

United States. Testosterone gel is an FDA-approved prescription medicine and a Schedule III controlled substance. The key steps:

  • Products. AndroGel 1% and 1.62%, Testim, Vogelxo, generic 1% and 1.62% gels and generic 2% solutions have current labels; Fortesta, Axiron, Androderm and Striant are no longer sold. [5], [62], [19]
  • 2009 to 2016. FDA required the boxed warning on secondary exposure (2009), the statement that benefit in "age-related" low testosterone is not established (2015) and warnings on abuse and dependence (2016). [71], [92], [94]
  • February 28, 2025. FDA told the makers of testosterone products to add the TRAVERSE results and blood-pressure warnings to their labels and to remove heart-risk language from boxed warnings. The AndroGel and Testim labels made these changes in July 2025. [92], [4], [7]
  • June 18, 2026. The Department of Health and Human Services (HHS) announced that FDA is requesting label changes: removing the age-related limitation, contraindicating testosterone only in metastatic prostate cancer, and revising the prostate-enlargement warning. These are requests: the current gel labels still carry the old wording. [95], [4]
  • Telehealth. Temporary rules let clinicians prescribe controlled medicines such as testosterone without an in-person visit through December 31, 2026; a permanent Drug Enforcement Administration (DEA) special-registration rule is still under review. [96], [97]

Canada. Schedule IV controlled substance, prescription-only. AndroGel 1%, Testim and Taro's 1% gel sachets are marketed, Taro's gel pump (approved September 18, 2026) is not yet, and no 1.62% gel is sold. [98], [16], [99]

United Kingdom. Class C controlled drug, prescription-only. Current gels are Testogel 16.2 mg/g, Irisel, Tostran and Testavan. [100], [101]

Australia. Schedule 4 (prescription-only), with extra controls on possession. Current topical products are Testogel 1%, Testavan and the AndroForte 5 cream. [102], [103]

European Union. Rules are national. France markets AndroGel 16.2 mg/g and Testavan, Ireland Testarzon 20 mg/g, and Spain the 50 mg Testogel sachet (1%), Testavan and Itnogen 20 mg/g, while Spain's Testogel 16.2 mg/g is authorised but not marketed; other member states were not checked. See TRT in Europe. [17], [18], [58], [104]

A "research use only" label or an overseas seller does not make a product legal, tested or the same as a licensed product.

Is testosterone gel banned in sport?

Yes. Testosterone in any form is on the World Anti-Doping Agency (WADA) Prohibited List in class S1, banned in and out of competition, and the 2027 list keeps that from January 1, 2027. Athletes with a medical need can apply for a therapeutic use exemption, which WADA grants only when low testosterone has an organic cause (such as a testicular or pituitary disorder), not for age, obesity or earlier steroid use. [105], [106], [107]

Who should be especially cautious?

  • Men living with children or a pregnant partner. Transfer is the gel-specific risk, and pregnant women should avoid contact with the application site. [4]
  • Men who want children now or soon. Testosterone suppresses sperm production; guidelines advise against it for men trying to conceive. [38], [79]
  • Men with prostate or breast cancer. Contraindicated on current US labels (known or suspected prostate cancer). [4]
  • Heart, kidney or liver disease, or uncontrolled high blood pressure. Fluid retention and blood-pressure rises can worsen these. [4]
  • High hematocrit. Several guidelines treat a high starting hematocrit as a reason for caution. [23], [28]
  • Sleep apnea. Untreated severe sleep apnea is a caution in guidelines and labels. [23], [4]
  • Women and children. Testosterone gel is not for women (see testosterone therapy for women) and is not established for anyone under 18. [4]
  • Drug-tested athletes. Banned at all times. [105]

Can testosterone gel be taken with other medicines?

The labels list three interactions:

  • Blood thinners (oral anticoagulants). Testosterone can change their effect; the labels advise more frequent blood-clotting tests (the international normalized ratio, or INR, and prothrombin time), especially when starting and stopping testosterone. [4]
  • Insulin and diabetes medicines. Testosterone can lower blood sugar and insulin needs. [4]
  • Corticosteroids. Together they can increase fluid retention. [4]

Testosterone can also lower thyroxine-binding globulin, which changes total thyroid hormone results without changing thyroid function. Skin products matter too: antiperspirant affects the underarm solution, and moisturizer and sunscreen slightly increase absorption of AndroGel 1.62% (washing and lotions). Bring a full list of everything you take, including supplements, to a pharmacist or doctor. [4], [9], [27]

Is testosterone gel available, and what does it cost?

Checked September 2026.

In the United States, generic 1% and 1.62% gels are sold by several makers, and FDA's drug shortage data list no testosterone shortage (updated September 26, 2026). [5], [108]

There is no single US price. As a reference point, pharmacies paid on average about $0.47 per gram for generic 1.62% gel in September 2026, about $35 for 30 days at 40.5 mg (2.5 g) a day, and about $0.41 per gram for generic 1% gel packets, about $61 for 30 days at 5 g a day; brand Testim cost about $3.78 per gram. What you pay depends on the pharmacy and insurance. In Medicare Part D in 2024, the average gross cost was $167.85 per fill for that combined generic entry and $1,148.50 per fill of brand AndroGel, before rebates. [109], [6]

France's AndroGel 16.2 mg/g and Testavan are not reimbursed. For other countries, see the TRT access guides. [17], [18]

What should be monitored while using testosterone gel?

The US gel labels ask for testosterone, PSA, hemoglobin, hematocrit, liver tests, cholesterol and blood pressure to be checked periodically; the numeric limits come from guidelines. Use this summary to prepare questions for your prescriber; it is not a personal testing plan. [4]

Why it mattersWhat labels and guidelines sayTracking category
Testosterone levelTiming depends on the product and guideline (timing); draw from an arm without gelBlood work; Libido; Energy Levels
HematocritLabels: before, at 3–6 months, then yearly. Endocrine Society: stop if above 54% until it falls. AUA: intervene at 54% or higher. VA: adjust above 51%, stop above 54%Blood work
PSA and prostateAUA: PSA before starting in men over 40. Endocrine Society: urology referral if PSA rises by more than 1.4 ng/mL in the first 12 months or exceeds 4.0 ng/mLBlood work; Urinary Symptoms
Blood pressureLabels: measure periodically; not for uncontrolled high blood pressureBlood Pressure
Skin and householdSite reactions; signs of virilization in children or women at homeSkin Health; Other
FertilitySemen analysis only if fertility matters; testosterone suppresses sperm productionOther (semen result)

[4], [23], [38], [24]

The European urology guideline monitors testosterone and hematocrit at 3, 6 and 12 months and then yearly. See TRT blood work and hematocrit on TRT. [28]

Write down the timing. For every testosterone result on gel, note the time you applied the gel that day (or that you had not yet applied it) and which arm the blood came from. A result without that context is hard to interpret. [4], [40]

What do people in public communities report?

Public forums hold every kind of gel story: men who feel better within weeks, men whose levels barely move after months, and men who stopped because of the daily routine, their skin or worry about their families. The accounts below come from public Reddit threads from the past year and are described without identifying anyone.

What do the positive reports look like?

Better energy, mood, sex drive and morning erections, sometimes within weeks. A man in his 20s on AndroGel 1.62% at 40.5 mg a day felt calmer and more energetic by his third week, then switched to injections only because he disliked the daily routine, and felt worse in the first weeks after the switch. A man in his 30s on 50 mg of AndroGel 1% noticed better mood, sleep and workout motivation within ten days. Another had felt well on 60 mg a day for years, until he raised the dose himself and developed erection problems within two months. [110], [111], [112]

Does everyone respond?

No, and "gel is not working" is a common topic. A man in his 40s went from 178 to 206 ng/dL after three months on one pump a day; his aches eased but his energy and sex drive did not, and he had sometimes put the gel on his thighs. A man in his 60s reported 280 before and 290 after seven months of AndroGel, and a man using one pump of 1.62% gel felt nothing after a month, with his level down from 13.3 to 11.3 nmol/L. A higher level did not always mean feeling better: one man reached 955 ng/dL on four pumps but felt little different from the 400s on two. [113], [114], [115], [116], [117]

Replies often suggest switching to injections. The labels point first to the basics: the product's own sites, the washing wait and when blood is drawn; after a genuine trial with low results, labels and the AUA support a dose change or another topical product. [4], [38]

Why do blood results confuse people?

Timing and contamination. One man's level came back at 96, below his pretreatment results, from blood drawn 24.5 hours after his last dose; another had missed the gel the day before his test. At the other extreme, a man on Tostran measured 10.3 nmol/L before his dose and 52.6 nmol/L three hours after it. With unexpectedly high results, one at 1,508 from an afternoon draw and one above 1,200 after gel on the forearms, contamination of the sample by gel on the skin was raised as a possible cause. These are the effects described in when blood should be drawn. [118], [119], [120], [121], [122]

What unwanted effects come up?

  • Skin. Acne and irritation limited to the application sites, and stinging on very dry shoulders. Attempts to boost absorption made things worse: one person scrubbed dry skin with salicylic acid and a derma roller before applying and got burning, and another tore their skin removing an adhesive dressing put over the site to protect a partner and child. [123], [124], [125], [126]
  • Off-label sites. One man's level jumped from 12.8 to 30.2 nmol/L after moving part of a larger dose to the scrotum, a site no US or UK gel label allows. [127]
  • Hematocrit. One man's hematocrit rose from 40% to 50% within two months on 50 mg of Testogel, with fatigue and head pressure; two weeks after stopping, it was 48%. He was also losing weight on tirzepatide and unsure how well hydrated he had been. [128]
  • Hair and testicles. A man in his 30s stopped Testogel after hair loss and testicular shrinkage; seven to eight months later his LH and FSH had recovered and his testosterone was back at the low end of the range. [129]
  • Swings and new symptoms. Some describe a lift for a few hours after applying, then a dip. One man started by a clinic on 100 mg of AndroGel 1% reported a pounding heartbeat, headaches and faster breathing within days. [130], [131]

What do people say about family, cost and switching?

Transfer shapes decisions: one person with young children and a pet asked for injections before starting gel, and the prescriber switched the order to weekly cypionate. Costs and access vary: one wife reported $53 a month for her husband's gel, a man in Germany switched to injections mainly because gel was expensive, and a man in Australia said his general practitioner would prescribe only gel. [132], [133], [134], [135]

People switching to injections often ask for an equivalent dose, and replies point out that none exists; the new dose has to be judged by new blood tests. Some who switched felt worse within days, which replies called too early to judge. And a man thinking of using his wife's Testogel for an extra boost at the gym changed his mind after replies explained it would suppress his own production. [117], [136], [137]

How can you judge a gel story?

Ask: Which product and strength, and how many presses or mg? Where was it applied, and how long before washing? When was blood drawn relative to the day's application, and from which arm? What else changed at the same time, such as weight loss, sleep treatment, other medicines or training? What happened a few months later?

These selected discussions show what people experience and what research should answer. They are not a survey of all users, a success rate or a substitute for the studies.

How does testosterone gel compare with other testosterone forms?

These are the forms most often weighed against gel. Status was checked in September 2026.

FormWhat it isRoute and labeled scheduleWhat stands outUS status
Testosterone gel (this guide)Testosterone in an alcohol gelTransdermal, daily; AndroGel 1.62%: 40.5 mg each morningSteady levels; hematocrit up about 3 points vs placebo; transfer warningApproved; Schedule III [4], [47]
Compounded testosterone creamPharmacy-made cream, different from Australia's approved AndroForte 5 creamSkin, daily; strength per prescriptionNo FDA-approved labelNot FDA approved [52]
Testosterone cypionateShort-acting ester in oilIntramuscular (into a muscle), 50–400 mg every 2–4 weeksPeaks and troughs; hematocrit up about 4 pointsApproved [138], [47]
Testosterone enanthateShort-acting ester; Xyosted autoinjectorXyosted: 75 mg weekly, subcutaneous (under the skin)Weekly self-injectionApproved [139]
Testosterone undecanoate injection (Aveed, Nebido)Long-acting esterAveed: 750 mg at start, at 4 weeks, then every 10 weeksFew injections; boxed warningApproved (Aveed) [140]
Oral testosterone undecanoate (Jatenzo, Kyzatrex, Tlando)Capsules taken with foodTwice dailyNo transfer; blood-pressure checksApproved [141]
NatestoNasal gel11 mg per dose (one 5.5 mg spray in each nostril), three times dailyNo transfer warningApproved [142]
Testosterone pellets (Testopel)Pellets implanted subcutaneously150–450 mg every 3–6 monthsHard to adjustApproved [143]

No trial ranks these forms on long-term outcomes. The practical differences are how often you dose, how much levels swing and hematocrit rises, how quickly the form clears and whether someone else can be exposed. [84], [47]

Common questions about testosterone gel

How much testosterone gel should I use?

The labels start at 40.5 mg (2 presses) of a 1.62% gel or 50 mg of a 1% gel once each morning, then adjust by blood tests: 20.25–81 mg for AndroGel 1.62%, and up to 100 mg for 1% gels. The right number of presses depends on the product, so your prescription and label decide it. [4], [1], [7] See typical protocols.

How long after applying testosterone gel can I shower, swim or have sex?

Wait at least 2 hours after AndroGel 1.62%, Testim and most other gels, 5 hours after AndroGel 1%, and 1 hour after UK Testogel before showering or swimming. For skin-to-skin contact, cover the dried site with a shirt or wash it first, whatever the time; transfer was still seen 12 hours after application in one study. [4], [1], [10], [76] See washing and protecting others.

Can I put testosterone gel on my stomach, thighs or scrotum?

Only if your product's label names that site. AndroGel 1% may go on the abdomen, and Tostran on the abdomen or inner thighs, but AndroGel 1.62%, Testim and UK Testogel are for the shoulders and upper arms only; abdominal application of 1.62% gel gave 30–40% lower exposure. No US or UK gel is labeled for the scrotum, where absorption is far higher. [1], [13], [4], [37], [51] See application sites.

Is testosterone gel as good as injections?

No trial has compared them head to head on symptoms or long-term outcomes. Both bring most men into the normal range; gels give steadier daily levels and, according to the Endocrine Society, are less likely to push hematocrit too high (a pooled analysis of trials could not show a clear gap), while injections are cheaper, do not transfer to others and are not a daily task. [84], [23], [47], [30] See the evidence.

How do I switch from gel to injections, and what dose is equivalent?

There is no validated conversion between a gel dose and an injection dose, because only a variable part of the gel is absorbed. Prescribers start the new form at its own labeled or guideline dose and check blood levels afterward. [4], [1], [84] See stopping and the cypionate guide.

Why is my testosterone still low on gel?

Common reasons are blood drawn before the day's dose (the lowest point), a missed application, washing too soon, an unlisted site, or simply absorbing less than average; in trials, about 1 in 8 to 1 in 4 men were outside the normal range at a given check. Labels respond by adjusting the dose, and switching brands raised levels in some men. [4], [38], [44] See blood-test timing.

Does testosterone gel cause hair loss?

It may. Gel raises DHT, the hormone behind male-pattern hair loss, more than a patch does, and the labels list hair loss (alopecia) among reactions reported after approval, but no study has shown that gel causes more hair loss than other forms. [2], [45], [4] See estrogen and DHT.

Glossary

Plain explanations of the medical, dosing and research terms used in this guide. Underlined terms in the text link here.

5-alpha reductase
An enzyme, found in skin and the prostate, that turns testosterone into DHT. It is why gel raises DHT more than a patch does.
Adverse event
A harmful or unwanted medical event reported after someone used a treatment. A report alone does not prove the treatment caused it.
Azoospermia
No sperm at all in a semen sample.
Bioequivalence
When two products deliver the same drug into the blood at the same rate and amount, within set limits (usually 80–125%). Testim and AndroGel are not bioequivalent.
Boxed warning
The most serious warning FDA puts on a US label, printed in a box at the top. Testosterone gels carry one about secondary exposure of children.
Buccal
Absorbed through the lining of the mouth, as with the discontinued Striant, which was held against the gum.
Controlled substance
A medicine whose prescribing and possession are restricted by law because it can be misused. Testosterone is Schedule III in the US, Schedule IV in Canada and Class C in the UK.
Controlled trial
A study that compares people who receive a treatment with a similar group who do not, often receiving a placebo instead. Randomly assigning people to each group makes the comparison fairer.
DHT (dihydrotestosterone)
A stronger hormone made from testosterone by 5-alpha reductase. It drives male-pattern hair growth and loss and prostate growth.
Ester
A chemical tail joined to testosterone in injectable forms, such as cypionate, that makes it release slowly from oil. Gel contains plain testosterone with no ester.
Estradiol
The main form of estrogen. In men it is made mostly from testosterone, so it rises when testosterone rises.
FSH (follicle-stimulating hormone)
A pituitary hormone that acts on the cells supporting sperm production. Testosterone therapy lowers it.
Gynecomastia
Growth of breast tissue in men, often tender at first. It is linked to a higher estrogen-to-testosterone balance.
Hematocrit
The share of the blood made up of red blood cells. Testosterone raises it, and most guidelines act when it reaches about 54%.
Hypogonadotropic hypogonadism
Low testosterone because the brain and pituitary send too little LH and FSH to the testicles. It can be present from birth or start later. Also called secondary hypogonadism.
Hypogonadism
Low testosterone caused by a problem in the testicles or in the brain and pituitary signals that control them, confirmed with symptoms and repeated morning blood tests.
LH (luteinizing hormone)
A pituitary hormone that tells the testicles to make testosterone. Testosterone therapy lowers it, often a lot.
MACE (major adverse cardiovascular events)
A combined measure used in heart-safety trials. In TRAVERSE it meant heart attack, stroke or death from heart disease.
Placebo
A dummy treatment with no active ingredient, used as a comparison in studies. In TRAVERSE, the placebo was a gel without testosterone.
Pre-dose level
A blood test taken in the morning before that day's gel, when levels are at their lowest. The US AndroGel 1.62% and Testim labels adjust the dose by it.
Primary hypogonadism
Low testosterone because the testicles themselves do not work well, even though the pituitary sends plenty of LH and FSH.
PSA (prostate-specific antigen)
A blood test for a protein made by the prostate. It rises slightly on testosterone and is used to decide whether prostate checks are needed.
Pump press (actuation)
One full push of a metered gel pump. The amount per press depends on the product: 20.25 mg for 1.62% gels and 12.5 mg for 1% gels.
Secondary exposure
Testosterone reaching someone other than the patient, usually by touching skin or clothing where gel was applied.
SHBG (sex hormone-binding globulin)
A blood protein that carries testosterone. Testosterone bound to it is not immediately available to tissues, so SHBG affects how much free testosterone there is.
Steady state
The point, after a few days of daily use, when levels follow the same pattern each day. For testosterone gel it is reached in about 2 to 3 days.
Subcutaneous (SC)
Injected into the fatty layer just under the skin, as with the Xyosted autoinjector.
Titration
Adjusting a dose in steps, usually based on blood tests and symptoms.
Transdermal
Absorbed through the skin into the blood, as with gels, solutions and patches.
TRT (testosterone replacement therapy)
Prescribed testosterone, by gel, injection or other forms, for men with low testosterone. It lowers the brain's LH and FSH signals, which can reduce or stop sperm production.
Virilization
Development of male traits, such as genital growth, pubic or facial hair and a deeper voice, in a child or woman exposed to testosterone.
WADA
The World Anti-Doping Agency, which publishes the list of substances banned in sport. Testosterone is banned at all times.
Weekly total
All the amounts given in one week, added together. For gel it is the amount applied, of which only a small share is absorbed, so it cannot be compared with an injection's weekly total.

How this guide was researched

This guide is built from a thorough review of the sources cited throughout it: product labels and product information from the United States, the United Kingdom, Canada, Australia and Europe, clinical guidelines, published clinical trials and studies, FDA and Federal Register records, and regulatory and price databases. We also reviewed public online forums where people describe their own experiences with testosterone gel.

The guide cites 143 sources, including 29 product labels and product information documents, 10 clinical guidelines and 41 original studies and case reports in people, plus 28 public community threads. Each type of source answers a different question. Labels, guidelines and trials show what was approved and measured. Regulatory records show what is sold and what changed. Personal accounts show what individual people experienced. Every numbered citation links to its entry below, labeled by source type.

How this guide was made

Research and drafting were AI-assisted. Every cited source was checked against the original, and the guide was reviewed and edited by Doserly before publication. It has not had an independent clinical review, and Doserly does not currently have medical reviewers. Doserly makes a medication and health-tracking app and runs Doserly Academy, both of which are promoted in this guide. Read our editorial policy for how guides are researched, updated and corrected.

This guide is for educational purposes. It summarizes what the reviewed sources report so the research is easier to understand; it is not medical advice. For a deeper dive, or to check any point for yourself, go straight to the cited sources.

Explore the sources

These are the documents cited in this guide. Labels, guidelines, studies and personal accounts answer different questions. A source being listed does not mean every statement on its page is endorsed.

Showing 143 sources

  1. 01

    ANDROGEL (testosterone gel) 1% for topical use, CIII ↗

    Product label (US)

    Full label reviewed.

    Detail: 50 mg each morning to the shoulders, upper arms and/or abdomen, up to 75 then 100 mg; about 10% absorbed; wait 5 hours before swimming or showering; levels back to pretreatment by the fifth day after stopping; a shirt prevented transfer in 38 couples.

  2. 02

    Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men ↗

    Human trial (randomized)

    Original abstract reviewed.

    Result detail: In 227 men, about 9–14% of the applied testosterone was absorbed; DHT rose 3.6- to 4.6-fold on gel vs 1.3-fold on a patch; LH and FSH fell in proportion to testosterone.

  3. 03

    Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparation ↗

    Human study

    Original abstract reviewed.

    Result detail: About 60% of the applied testosterone was still on the skin at 8 hours and about 14% after a water wash.

  4. 04

    ANDROGEL (testosterone gel) 1.62% for topical use, CIII ↗

    Product label (US)

    Full label reviewed.

    Detail: 40.5 mg (2 pump presses) each morning to the shoulders and upper arms only, 20.25–81 mg, titrated on a pre-dose morning level at about 14 and 28 days to stay within 350–750 ng/dL; wait 2 hours before washing; boxed warning on secondary exposure; carries the TRAVERSE results.

  5. 05

    Drugs@FDA application records for topical, transdermal and buccal testosterone (openFDA) ↗

    FDA product listing

    Structured data reviewed.

    Detail: Approval dates and therapeutic-equivalence codes: AndroGel 1% (2000) and its generics AB1; Testim (2002), its generic and the Vogelxo packet AB2; Vogelxo pump BX; AndroGel 1.62% (2011) pump generics AB; 2% solution generics AT; Fortesta, Axiron, Androderm and Striant discontinued.

  6. 06

    Medicare Part D Spending by Drug, data year 2024: generic testosterone and brand entries ↗

    Government spending data (US)

    Structured data reviewed.

    Detail: Generic plain testosterone (the entry named 'Testosterone', which covers generic gels and solutions): 556,670 claims (fills, including refills) for 132,638 people, $167.85 average gross spending per claim; AndroGel brand: 3,365 claims, $1,148.50 per claim, before rebates.

  7. 07

    TESTIM (testosterone gel) 1%, CIII ↗

    Product label (US)

    Full label reviewed.

    Detail: One 50 mg tube each morning to the shoulders and/or upper arms, not the abdomen or genitals; up to 100 mg after a pre-dose level at about 14 days; 74% of 192 men in range at day 90; may have an alcoholic or musk odor.

  8. 08

    VOGELXO (testosterone gel) 1%, CIII ↗

    Product label (US)

    Full label reviewed.

    Detail: 50 mg daily, up to 100 mg; tube, packet and pump; in 48 couples, unprotected partner exposure rose 2.8-fold, with less than 10% rise when a shirt was worn or the site washed; hand washing removed 99% of residue.

  9. 09

    Testosterone topical solution USP, 30 mg/1.5 mL per actuation (Lupin) ↗

    Product label (US)

    Full label reviewed.

    Detail: Generic of the withdrawn Axiron: 60 mg (one press to each armpit) each morning, 30–120 mg, blood drawn 2–8 hours after application; 84.1% in range at day 120; antiperspirant applied first lowered absorption by up to 33%.

  10. 10

    Testogel 16.2 mg/g gel: summary of product characteristics ↗

    Product information (UK)

    Full product information reviewed.

    Detail: 40.5 mg daily to the shoulders and upper arms, up to 81 mg; wait at least 1 hour before showering; sunscreen or lotion does not reduce efficacy; levels back to baseline 72–96 hours after the last dose; no special storage conditions.

  11. 11

    Testogel 40.5 mg transdermal gel in sachet: summary of product characteristics ↗

    Product information (UK)

    Full product information reviewed.

    Detail: One 2.5 g sachet contains 40.5 mg of testosterone; no special storage conditions.

  12. 12

    Irisel 16.2 mg/g transdermal gel: summary of product characteristics ↗

    Product information (UK)

    Full product information reviewed.

    Detail: 40.5 mg daily; first authorised June 18, 2026; cover the site to prevent transfer to other people and pets.

  13. 13

    Tostran 20 mg/g transdermal gel: summary of product characteristics ↗

    Product information (UK)

    Full product information reviewed.

    Detail: 60 mg (3 g) daily to the abdomen or both inner thighs, up to 80 mg; blood drawn 2 hours after application at about day 14; about 12% absorbed; store at or below 25 °C.

  14. 14

    Testavan 20 mg/g transdermal gel: summary of product characteristics ↗

    Product information (UK)

    Full product information reviewed.

    Detail: 23 mg (one press) each morning with an applicator to the upper arm and shoulder, up to 69 mg; blood drawn 2–4 hours after dosing; lower delivery from the abdomen or thigh; wait 2 hours before washing.

  15. 15

    Testavan 2% testosterone gel: Australian product information ↗

    Product information (Australia)

    Full product information reviewed.

    Detail: Same schedule as the UK product; store below 25 °C.

  16. 16

    Drug Product Database: testosterone products and status history ↗

    Regulator database (Canada)

    Structured database records reviewed.

    Detail: AndroGel 1%, Testim and Taro gel sachets marketed; Taro gel pump approved, not marketed; Androderm cancelled 2021–22 and Axiron December 4, 2017; no 1.62% gel in Canada; all testosterone products listed under Schedule IV.

  17. 17

    ANDROGEL 16,2 mg/g, gel transdermique (Base de données publique des médicaments) ↗

    Regulator database (France)

    Original record reviewed.

    Detail: AndroGel 16.2 mg/g marketed since February 14, 2018; not reimbursed.

  18. 18

    TESTAVAN 20 mg/g, gel transdermique (Base de données publique des médicaments) ↗

    Regulator database (France)

    Original record reviewed.

    Detail: Authorised April 27, 2018; marketing declared September 20, 2022; free price, not reimbursed.

  19. 19

    21 CFR 1308.13 Schedule III (anabolic steroids) ↗

    Regulation (US)

    Original page reviewed.

    Detail: Anabolic steroids, including testosterone, are Schedule III.

  20. 20

    AndroGel 1% (testosterone gel): Product Monograph (Canada) ↗

    Product monograph (Canada)

    Full label reviewed.

    Detail: 5 g (50 mg) daily, up to 7.5 g then 10 g; lower limit of normal given as 10.3 nmol/L (300 ng/dL).

  21. 21

    Testim 1% (testosterone gel): Product Monograph (Canada) ↗

    Product monograph (Canada)

    Full label reviewed.

    Detail: 50 mg daily, morning level about 7–14 days after starting, at most 100 mg a day.

  22. 22

    Testogel 1% (testosterone) gel: Australian product information ↗

    Product information (Australia)

    Full product information reviewed.

    Detail: 50 mg daily, up to 100 mg in 2.5 g steps, adjusted on a morning level before application; the 25 mg sachet is not currently marketed; store below 25 °C.

  23. 23

    Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: 50–100 mg of 1% gel, 20.25–81 mg of 1.62% gel or 40–70 mg of 2% gel daily; check testosterone 2–8 hours after application after at least a week; aim for the mid-normal range.

  24. 24

    Evaluation for and Management of Males with Low Testosterone: Recommendations for Use ↗

    Health-system clinical recommendations

    Original full text reviewed.

    Detail: 1–4 pumps of 1.62% gel daily; blood 2–8 hours after application once at steady state; adjust above 900 ng/dL; notes higher cost, skin irritation and transfer.

  25. 25

    Canadian Urological Association guideline on testosterone deficiency in men: Evidence-based Q&A ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: 5–10 g of 1% gel a day; target 14–17 nmol/L; notes transfer risk and variable absorption; changes expected after 3 months or longer.

  26. 26

    Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: 50–100 mg of 1% Testogel, 40–70 mg of Tostran, 23–46 mg of Testavan or 20.25–81 mg of the 16.2 mg/g pump daily; blood 2–6 hours after application, away from the application site; avoid showering or swimming within 6 hours.

  27. 27

    Testosterone gel 1.62% metered pump (Xiromed) ↗

    Product label (US)

    Full label reviewed.

    Detail: Generic 1.62% gel with the AndroGel 1.62% dosing; moisturizer 1 hour after application raised average exposure 14% and sunscreen 8%.

  28. 28

    EAU Guidelines on Sexual and Reproductive Health, Chapter 3: Male Hypogonadism ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Use gels rather than long-acting depots when starting treatment in men at high risk; monitor testosterone and hematocrit at 3, 6 and 12 months, then yearly.

  29. 29

    European Academy of Andrology guidelines on investigation, treatment and monitoring of functional hypogonadism in males ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: For functional hypogonadism, suggests a transdermal preparation to start treatment; against testosterone when fertility is desired; review at 3 and 12 months, then yearly.

  30. 30

    Testosterone Treatment in Adult Men With Age-Related Low Testosterone: A Clinical Guideline From the American College of Physicians ↗

    Clinical practice guideline (now listed as inactive)

    Original abstract reviewed.

    Detail: For age-related low testosterone, suggested considering intramuscular rather than transdermal forms because costs were lower and effectiveness and harms similar.

  31. 31

    Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men ↗

    Human trial (randomized)

    Original abstract reviewed.

    Result detail: 227 men on 50 or 100 mg of 1% gel or a patch: sexual function and mood improved by day 30; lean mass rose 2.74 kg on 100 mg, 1.28 kg on 50 mg and 1.20 kg on the patch; skin irritation 5.5% on gel vs 66% on the patch.

  32. 32

    Effect of Testosterone Replacement Therapy on Sexual Function and Hypogonadal Symptoms in Men with Hypogonadism ↗

    Human trial (randomized; TRAVERSE substudy)

    Original abstract reviewed.

    Result detail: In 1,161 men with low libido, sexual activity rose about 0.5 acts a day more than placebo, lasting to 24 months; erections did not improve.

  33. 33

    Effects of Testosterone Treatment in Older Men ↗

    Human trial (randomized)

    Original full text reviewed.

    Result detail: 790 men aged 65 or older; a year of 1% gel improved sexual function and mood a little; no vitality benefit; walking improved slightly across all participants but not in the physical function trial.

  34. 34

    AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function ↗

    Human trial (randomized)

    Original abstract reviewed.

    Result detail: Testim pivotal trial in 406 men: on 100 mg, lean mass rose 1.7 kg and body fat fell 1.2 percentage points by day 90, significantly more than on the patch or placebo; spontaneous erections and desire improved vs placebo.

  35. 35

    Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men ↗

    Human study (open-label extension)

    Original abstract reviewed.

    Result detail: Up to 42 months in 163 men: benefits maintained, spine bone density rose, estradiol-to-testosterone ratio doubled; mild skin irritation in 12; 3 prostate cancers found on biopsy after PSA rises; no placebo group.

  36. 36

    Efficacy of Testosterone Replacement Therapy in Correcting Anemia in Men With Hypogonadism: A Randomized Clinical Trial ↗

    Human trial (randomized; TRAVERSE substudy)

    Original full text reviewed.

    Result detail: Anemia corrected at 12 months in 45.0% (152 of 338) on testosterone vs 33.9% (122 of 360) on placebo.

  37. 37

    Pharmacokinetics and relative bioavailability of absorbed testosterone after administration of a 1.62% testosterone gel to different application sites in men with hypogonadism ↗

    Human study (crossover)

    Original abstract reviewed.

    Result detail: Abdomen-only application gave about 30–40% lower exposure than the upper arms and shoulders; steady state after 2 days.

  38. 38

    Evaluation and Management of Testosterone Deficiency: AUA Guideline ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Topicals bring 74–87% of men into the normal range; skin reactions 3–16%; first check 2–4 weeks after starting a gel, applied on the test day; target 450–600 ng/dL; switching to another topical product is a reasonable option; no testosterone for men trying to conceive.

  39. 39

    The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Gel samples 2–4 hours after application, avoiding skin contamination; target 15–30 nmol/L; gels and long-acting undecanoate have the least effect on hematocrit.

  40. 40

    Falsely elevated serum testosterone measurements resulting from testosterone topical gel contamination of the venipuncture site: Case Series and retrospective review ↗

    Human study (case series)

    Original full text reviewed.

    Result detail: Of 578 gel users over 13 years, 48 had a result above 1,000 ng/dL; gel on the draw site was strongly supported as the cause in 7.

  41. 41

    Recognition, prevalence and prevention of falsely high serum testosterone concentrations in testosterone gel users ↗

    Human study

    Original abstract reviewed.

    Result detail: Blood drawn from the arm where gel was applied read 33.2 nmol/L vs 14.2 from the other arm.

  42. 42

    Evaluation of the pharmacokinetic profiles of the new testosterone topical gel formulation, Testim, compared to AndroGel ↗

    Human study (crossover)

    Original abstract reviewed.

    Result detail: In 29 men given one 50 mg dose of each, Testim gave 30% higher total testosterone exposure and 47% higher free testosterone; not bioequivalent.

  43. 43

    Testim 1% testosterone gel for the treatment of male hypogonadism ↗

    Review

    Original abstract reviewed.

    Detail: Testim gave about 30% more total testosterone exposure than AndroGel (90% CI 8% to 57%); over 12 months in 371 men, lean mass rose 2.2 kg.

  44. 44

    Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men ↗

    Human study (retrospective)

    Original abstract reviewed.

    Result detail: In 75 men switched after a poor response, AndroGel to Testim raised average testosterone from 311 to 484 ng/dL; Testim to AndroGel did not raise levels.

  45. 45

    Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men ↗

    Human study (crossover)

    Original abstract reviewed.

    Result detail: Gel gave a flatter average daily profile than a patch, but each man's peak came at a different time; DHT-to-testosterone ratio 2–3 times higher on gel.

  46. 46

    Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception: an integrated analysis ↗

    Human study (pooled analysis)

    Original abstract reviewed.

    Result detail: 1,549 healthy men; sperm back to 20 million/mL in 67% by 6 months, 90% by 12, 96% by 16 and 100% by 24 months.

  47. 47

    The Effect of Route of Testosterone on Changes in Hematocrit: A Systematic Review and Bayesian Network Meta-Analysis of Randomized Trials ↗

    Meta-analysis of trials

    Original abstract reviewed.

    Result detail: 29 trials; hematocrit rise vs placebo about 3.0 points for gel, 4.0 for enanthate or cypionate injections, 1.6 for undecanoate injections and 1.4 for patches.

  48. 48

    Testosterone 2% gel can normalize testosterone concentrations in men with low testosterone regardless of body mass index ↗

    Human study (analysis of trial data)

    Original abstract reviewed.

    Result detail: At day 90, 79.1%, 79.5% and 73.8% were in range from the lightest to the heaviest third of men; heavier men needed higher doses; skin reactions 16.1%.

  49. 49

    Absorption of testosterone gel 1% (Testim) from three different application sites ↗

    Human study (crossover)

    Original abstract reviewed.

    Result detail: Levels were highest from the shoulders and upper arms, lower from the chest and abdomen and lowest from the legs; all sites reached the normal range.

  50. 50

    Testosterone gel 1% (Strides Pharma) ↗

    Product label (US)

    Full label reviewed.

    Detail: Generic AndroGel 1%-type gel: wait at least 5 hours before showering or swimming; not for the penis or scrotum; a postmarketing report of possible transfer through towels and sheets.

  51. 51

    Pharmacokinetics of testosterone cream applied to scrotal skin ↗

    Human study

    Original abstract reviewed.

    Result detail: 25 mg of cream on scrotal skin kept testosterone in the physiological range for 16 hours, a far smaller dose than non-scrotal skin needs; DHT rose.

  52. 52

    AndroForte 5 (testosterone 5% w/v cream): Australian product information ↗

    Product information (Australia)

    Full product information reviewed.

    Detail: 25 mg (0.5 mL) daily to the scrotum or 100 mg (2 mL) to the upper body; the only approved product labeled for scrotal use among those reviewed.

  53. 53

    Reduction in 24-hour plasma testosterone levels in subjects who showered 15 or 30 minutes after application of testosterone gel ↗

    Human study (crossover)

    Original abstract reviewed.

    Result detail: Average testosterone was 994 ng/dL without an early shower, 401 after showering at 30 minutes and 320 at 15 minutes; small study in transgender men.

  54. 54

    Effects of skin washing on systemic absorption of testosterone in hypogonadal males after administration of 1.62% testosterone gel ↗

    Human study (crossover)

    Original abstract reviewed.

    Result detail: Washing 2 or 6 hours after application lowered exposure by 10–14%; washing at 10 hours had no effect.

  55. 55

    Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men ↗

    Human trial (randomized)

    Original abstract reviewed.

    Result detail: AndroGel 1.62% pivotal trial: 81.6–82.5% of men on gel had average testosterone of 300–1,000 ng/dL vs 28.6–37.0% on placebo.

  56. 56

    Determination that AXIRON (testosterone) topical solution was not withdrawn from sale for reasons of safety or effectiveness ↗

    Regulatory notice (US)

    Original page reviewed.

    Detail: The Axiron brand application was withdrawn effective July 23, 2018; generic 2% solutions remain.

  57. 57

    Testogel 50 mg transdermal gel in sachet: summary of product characteristics ↗

    Product information (UK)

    Listing and headline items reviewed.

    Detail: The older 1% sachet, now marked discontinued; UK Testogel is the 16.2 mg/g pump and 40.5 mg sachet.

  58. 58

    Testarzon 20 mg/g transdermal gel (HPRA authorised medicines) ↗

    Regulator database (Ireland)

    Original record reviewed.

    Detail: Licensed April 13, 2018; listed as marketed.

  59. 59

    FORTESTA (testosterone) gel prescribing information (S-029) ↗

    Product label (US, discontinued product)

    Full label reviewed.

    Detail: 2% gel, 40 mg to the front and inner thighs, 10–70 mg, titrated on a level 2 hours after application; 77.5% (100 of 129) in range; skin reactions 16.1%.

  60. 60

    A novel testosterone 2% gel for the treatment of hypogonadal males ↗

    Human study (single-arm)

    Original abstract reviewed.

    Result detail: Fortesta pivotal trial: 77.5% (100 of 129) in the normal range at day 90.

  61. 61

    Determination that FORTESTA (testosterone) gel was not withdrawn from sale for reasons of safety or effectiveness ↗

    Regulatory notice (US)

    Original page reviewed.

    Detail: The Fortesta brand was discontinued after a sponsor letter of December 1, 2023, not for safety reasons.

  62. 62

    Testosterone gel 2%, metered (Actavis, ANDA 204571) ↗

    Product listing (US)

    Original record reviewed.

    Detail: The only generic of Fortesta; marketing ended January 31, 2026.

  63. 63

    ANDRODERM (testosterone transdermal system) prescribing information (S-036) ↗

    Product label (US, discontinued product)

    Full label reviewed.

    Detail: One 4 mg/day patch each night, 2–6 mg/day, early-morning level at about 2 weeks; skin reactions in 28% with current patches and 48% with older ones; remove before an MRI.

  64. 64

    Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men ↗

    Human study

    Original abstract reviewed.

    Result detail: The patch normalized morning testosterone in 93% and followed the natural daily rhythm; 9% stopped for skin reactions.

  65. 65

    Transfer of transdermally applied testosterone to clothing: a comparison of a testosterone patch versus a testosterone gel ↗

    Human study

    Original abstract reviewed.

    Result detail: T-shirts worn over gel held a median 6,763 micrograms of testosterone vs 25 micrograms over a patch.

  66. 66

    Determination that listed drug products (including ANDRODERM, NDA 020489) were not withdrawn from sale for reasons of safety or effectiveness ↗

    Regulatory notice (US)

    Original page reviewed.

    Detail: Lists Androderm strengths as no longer marketed, not for safety reasons.

  67. 67

    STRIANT (testosterone buccal system) prescribing information (S-012) ↗

    Product label (US, withdrawn product)

    Full label reviewed.

    Detail: 30 mg to the gum above an incisor twice daily; 86.6% in range; gum or mouth irritation 9.2%; 4.1% stopped for mouth side effects.

  68. 68

    The long-term efficacy and safety of a testosterone mucoadhesive buccal tablet in testosterone-deficient men ↗

    Review

    Original abstract reviewed.

    Detail: Gum problems in 5.6–16.3% of men in Striant studies; 90% found twice-daily use acceptable.

  69. 69

    Withdrawal of approval of 16 new drug applications (includes STRIANT, NDA 021543) ↗

    Regulatory notice (US)

    Original page reviewed.

    Detail: Striant's approval was withdrawn effective June 15, 2020.

  70. 70

    Topical testosterone (Testogel): risk of harm to children following accidental exposure ↗

    Regulator safety notice (UK)

    Original page reviewed.

    Detail: A UK report of a child with faster growth and genital enlargement from a parent's gel; advises hand washing, covering the dried site and washing it before contact.

  71. 71

    Fortesta (NDA 021463) medication error prevention review, with adverse event search ↗

    FDA review

    Original document reviewed.

    Detail: Counted 30 reports of secondary exposure with adverse events in children and adults, 2001–2009, and recalls FDA's May 7, 2009 announcement requiring a boxed warning and a Medication Guide.

  72. 72

    AndroGel 1% prescribing information with new boxed warning (S-022) ↗

    Product label (US, historical)

    Full label reviewed.

    Detail: The first label version carrying the boxed warning on secondary exposure of children.

  73. 73

    Premature Pubarche due to Exogenous Testosterone Gel or Intense Diaper Rash Prevention Cream Use: A Case Series ↗

    Human report (case series)

    Original abstract reviewed.

    Result detail: All 5 children exposed to a relative's gel were moderately to severely virilized, and all 5 grew faster than expected.

  74. 74

    Virilization of young children after topical androgen use by their parents ↗

    Human report (case series)

    Original abstract reviewed.

    Result detail: Young children were virilized through contact with parents using skin androgens; the parents were unaware; signs regressed when contact stopped.

  75. 75

    Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies ↗

    Case report and review

    Original abstract reviewed.

    Detail: A woman developed high testosterone from her partner's gel; transfer to women and children is possible and clinically relevant.

  76. 76

    Serum testosterone levels in non-dosed females after secondary exposure to 1.62% testosterone gel: effects of clothing barrier on testosterone absorption ↗

    Human study

    Original abstract reviewed.

    Result detail: A T-shirt prevented transfer from the upper arms and shoulders and cut transfer from the abdomen by about 40–48%; the risk lasted at least 12 hours.

  77. 77

    Effect of application site, clothing barrier, and application site washing on testosterone transfer with a 1.62% testosterone gel ↗

    Human study

    Original abstract reviewed.

    Result detail: Washing the application site before contact brought the partner's levels back to baseline.

  78. 78

    A new combination of testosterone and nestorone transdermal gels for male hormonal contraception ↗

    Human trial (randomized)

    Original abstract reviewed.

    Result detail: In healthy men, testosterone gel alone lowered sperm to 1 million/mL or less in 23%, and in 88–89% when a progestin gel was added.

  79. 79

    Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020; amended 2024) ↗

    Clinical practice guideline

    Original full text reviewed.

    Detail: Clinicians should not prescribe testosterone to men interested in current or future fertility.

  80. 80

    Comparison of the Effects of Testosterone Gels, Injections, and Pellets on Serum Hormones, Erythrocytosis, Lipids, and Prostate-Specific Antigen ↗

    Human study (retrospective)

    Original abstract reviewed.

    Result detail: Hematocrit above 50% in 12.8% on gels, 35.1% on pellets and 66.7% on injections.

  81. 81

    The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men ↗

    Human study (registry)

    Original abstract reviewed.

    Result detail: Hematocrit above 50% in 25 of 498 men on gel vs 69 of 304 on long-acting undecanoate injections; non-randomized, one center.

  82. 82

    Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE) ↗

    Human trial (randomized)

    Original abstract reviewed.

    Result detail: 5,204 men on daily 1.62% gel or placebo gel; heart attack, stroke or heart death 7.0% vs 7.3% (hazard ratio 0.96); mean treatment 21.7 months.

  83. 83

    One-year efficacy and safety study of a 1.62% testosterone gel in hypogonadal men ↗

    Human study (open-label extension)

    Original abstract reviewed.

    Result detail: At day 364, 77.9% of men continuing active gel were in the normal range.

  84. 84

    Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations ↗

    Systematic review

    Original abstract reviewed.

    Detail: Found hardly any studies comparing gel with injections directly; recommendations rest mainly on non-randomized data.

  85. 85

    Medication adherence and treatment patterns for hypogonadal patients treated with topical testosterone therapy: a retrospective medical claims analysis ↗

    Human study (claims data)

    Original abstract reviewed.

    Result detail: Of 15,435 men starting a topical product, 34.7% were still on it at 6 months and 15.4% at 12 months.

  86. 86

    Pharmacokinetics and drying time of testosterone 2% gel in men with hypogonadism: a multicenter, open-label, single-arm trial ↗

    Human study (single-arm)

    Original abstract reviewed.

    Result detail: 2% thigh gel dried in a median 2.4 minutes; levels reached the normal range at a median 2.9 hours; steady state in about 1.1 days.

  87. 87

    Testosterone Treatment and Fractures in Men with Hypogonadism ↗

    Human trial (randomized; TRAVERSE substudy)

    Original abstract reviewed.

    Result detail: Clinical fractures 91 of 2,601 (3.50%) vs 64 of 2,603 (2.46%).

  88. 88

    Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical Trial ↗

    Human trial (randomized; TRAVERSE substudy)

    Original abstract reviewed.

    Result detail: No significant reduction in progression from prediabetes to diabetes (overall P=0.49).

  89. 89

    Depressive Syndromes in Men With Hypogonadism in the TRAVERSE Trial: Response to Testosterone-Replacement Therapy ↗

    Human trial (randomized; TRAVERSE substudy)

    Original abstract reviewed.

    Result detail: No improvement in late-life persistent depressive disorder (49 men qualified); small improvements in mood and energy.

  90. 90

    Single-arm study of testosterone gel replacement therapy and ambulatory blood pressure outcomes in men with hypogonadism ↗

    Human study (single-arm)

    Original abstract reviewed.

    Result detail: In 169 men, 24-hour systolic blood pressure rose an average of 1.9 mm Hg after 16 weeks of 1.62% gel.

  91. 91

    Comparative Safety of Testosterone Dosage Forms ↗

    Human study (observational)

    Original abstract reviewed.

    Result detail: New users of injections had more heart attacks, unstable angina or strokes than new gel users (hazard ratio 1.26); patches and gels were similar; association only.

  92. 92

    FDA issues class-wide labeling changes for testosterone products ↗

    Regulator notice (US)

    Original page reviewed.

    Detail: Adds TRAVERSE results and blood-pressure warnings to testosterone labels, removes boxed-warning language on heart risk and keeps the age-related limitation of use.

  93. 93

    Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial ↗

    Human trial (randomized; TRAVERSE substudy)

    Original full text reviewed.

    Result detail: High-grade prostate cancer 5 of 2,596 (0.19%) vs 3 of 2,602 (0.12%); not significant; men with PSA above 3.0 ng/mL were excluded.

  94. 94

    ANDRODERM supplement approval letter S-034 (abuse and dependence labeling) ↗

    FDA approval letter

    Original document reviewed.

    Detail: Adds the class-wide warning on abuse and dependence of testosterone.

  95. 95

    HHS Announces Requested Updates to Testosterone Therapy Product Labels ↗

    Regulator notice (US)

    Original page reviewed.

    Detail: FDA is requesting removal of the age-related limitation, a contraindication only in metastatic prostate cancer, and a revised prostate-enlargement warning; requested, not yet in labels (checked September 2026).

  96. 96

    Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications ↗

    Regulation (US)

    Original page reviewed.

    Detail: Flexibilities run from January 1 to December 31, 2026.

  97. 97

    OIRA review record: Special Registrations for Telemedicine (RIN 1117-AB40), final rule stage ↗

    Regulatory record (US)

    Original page reviewed.

    Detail: The DEA special-registration final rule is under review, not published (checked September 2026).

  98. 98

    Controlled Drugs and Substances Act (S.C. 1996, c. 19), Schedule IV ↗

    Legislation (Canada)

    Original page reviewed.

    Detail: Anabolic steroids, including testosterone, are Schedule IV.

  99. 99

    Taro-Testosterone Gel Pump 1% (12.5 mg per actuation): Product Monograph (Canada) ↗

    Product monograph (Canada)

    Full label reviewed.

    Detail: Approved September 18, 2026; not yet marketed.

  100. 100

    Misuse of Drugs Act 1971, Schedule 2 Part III (Class C drugs) ↗

    Legislation (UK)

    Original page reviewed.

    Detail: Testosterone is a Class C controlled drug.

  101. 101

    Testosterone medicines with current UK product information (electronic medicines compendium) ↗

    Product information listings (UK)

    Current listings reviewed.

    Detail: Current UK testosterone gels are Testogel 16.2 mg/g (pump and 40.5 mg sachet), Irisel, Tostran and Testavan; the Testogel 50 mg sachet is marked discontinued. A listing shows authorisation, not stock.

  102. 102

    Therapeutic Goods (Poisons Standard, June 2026) Instrument 2026 ↗

    Legislation (Australia)

    Original page reviewed.

    Detail: Testosterone is Schedule 4 (prescription only), with Appendix D controls on possession.

  103. 103

    Testosterone medicines with current Australian product information (TGA) ↗

    Product information listings (Australia)

    Current product information documents reviewed.

    Detail: Current topical products are Testogel 1% (50 mg sachet and pump), Testavan 2% and AndroForte 5 cream; cancellation dates for other products were not verified.

  104. 104

    CIMA: authorised testosterone medicines in Spain, with marketing status ↗

    Regulator database (Spain)

    Structured data reviewed.

    Detail: Marketed topical products: Testogel 50 mg sachets, Testavan 20 mg/g and Itnogen 20 mg/g; Testogel 16.2 mg/g and Testim are authorised but not marketed.

  105. 105

    World Anti-Doping Code International Standard: Prohibited List 2026 ↗

    Anti-doping rule

    Original document reviewed.

    Detail: Testosterone is an S1 anabolic agent, prohibited at all times.

  106. 106

    World Anti-Doping Code International Standard: Prohibited List 2027 ↗

    Anti-doping rule

    Original document reviewed.

    Detail: Keeps testosterone prohibited at all times.

  107. 107

    TUE Physician Guidelines: Male Hypogonadism, Version 9 ↗

    Anti-doping guidance

    Original document reviewed.

    Detail: Exemptions only for organic hypogonadism, not functional low testosterone from aging, obesity or earlier steroid use.

  108. 108

    FDA Drug Shortages data (openFDA) ↗

    Regulator database (US)

    Structured data reviewed.

    Detail: No current, resolved or discontinued shortage record for any testosterone product.

  109. 109

    NADAC (National Average Drug Acquisition Cost) 2026: testosterone topical products ↗

    Government price data (US)

    Structured data reviewed.

    Detail: What pharmacies pay, not what patients pay: generic 1.62% pump $0.47 per gram, generic 1% 50 mg packets $0.41 per gram, Testim brand $3.78 per gram, 2% solution $0.51 per mL.

  110. 110

    Switched from AndroGel to Injections ↗

    Community account

    Public thread reviewed: opening post and 4 comments.

    Detail: A man in his 20s started AndroGel 1.62% for low energy, mood and anxiety concerns and felt calmer and more energetic by week three.

  111. 111

    Androgel vs intravenous application ↗

    Community account

    Public thread reviewed: opening post and 10 comments.

    Detail: A man in his 30s bought AndroGel abroad after years of symptoms and earlier discussions in which his testosterone had been considered within range.

  112. 112

    TRT dosing: feel amazing at >60 mg daily gel, then suddenly ED issues ↗

    Community account

    Public thread reviewed: opening post and 2 comments.

    Detail: The poster had used testosterone gel at 60 mg daily for years with relief of earlier fatigue, mood, libido, and erection problems.

  113. 113

    Any tips for getting gel to work better? ↗

    Community account

    Public thread reviewed: opening post and 37 comments.

    Detail: A man in his 40s started testosterone gel for low testosterone, aches, low energy, and low libido.

  114. 114

    Androgel didn't work, going to injections ↗

    Community account

    Public thread reviewed: opening post and 8 comments.

    Detail: A man in his 60s said seven months of regular AndroGel use made no noticeable difference to libido, energy, strength, or clarity.

  115. 115

    No changes after a month on Androgel ↗

    Community account

    Public thread reviewed: opening post and 18 comments.

    Detail: A man in his 30s used one pump of AndroGel daily for a month because of erectile problems and felt no improvement.

  116. 116

    Just switched from gel to Im… ↗

    Community account

    Public thread reviewed: opening post and 4 comments.

    Detail: A man in his 30s used two daily pumps of 1.62% gel for three months after two differing pretreatment testosterone results.

  117. 117

    Is 100 mg/mL Testosterone Cypionate per week equivalent to 4 pumps of Androgel per day? ↗

    Community account

    Public thread reviewed: opening post and 7 comments.

    Detail: A man in his 50s had used AndroGel for several years, increasing from two to four pumps daily.

  118. 118

    On Androgel and having absorption issues ↗

    Community account

    Public thread reviewed: opening post and 7 comments.

    Detail: A man in his 30s with Klinefelter syndrome started AndroGel after several low testosterone results and symptoms.

  119. 119

    Lower testosterone after starting T Gel🤔 ↗

    Community account

    Public thread reviewed: opening post and 32 comments.

    Detail: After one month using 1% testosterone gel, the OP found that measured testosterone was lower than before treatment, having missed the application the day before testing.

  120. 120

    large peak/trough swings on Tostran. What should I discuss with my endo ↗

    Community account

    Public thread reviewed: opening post and 1 comments.

    Detail: A man in his 30s uses Tostran after treatment for testicular cancer and reports better libido and arousal alongside episodes of exhaustion and irritability.

  121. 121

    Abnormally high results on androgel ↗

    Community account

    Public thread reviewed: opening post and 16 comments.

    Detail: The poster has used AndroGel for nearly a year and is trying to understand unexpectedly high blood-test results.

  122. 122

    Gel to injections ↗

    Community account

    Public thread reviewed: opening post and 13 comments.

    Detail: After about 17 months on AndroGel, the poster felt the gel was not worthwhile despite earlier and recent high testosterone readings.

  123. 123

    Skin problems using Testogel ↗

    Community account

    Public thread reviewed: opening post and 4 comments.

    Detail: After low testosterone results, the poster used Testogel for three months and felt better at first.

  124. 124

    Just started with testosterone gel - I have many questions. ↗

    Community account

    Public thread reviewed: opening post and 1 comments.

    Detail: A few days after starting testosterone gel, the poster asked how much it might raise their levels and how to improve absorption.

  125. 125

    Testosterone Gel - maximize skin absorpiton ↗

    Community account

    Public thread reviewed: opening post and 22 comments.

    Detail: The poster had recently been prescribed an alcohol-based testosterone gel after their doctor declined to prescribe injections.

  126. 126

    New on Androgel, can I get some advice and opinions? ↗

    Community account

    Public thread reviewed: opening post and 11 comments.

    Detail: The poster had just started 50mg AndroGel and wanted to limit skin contact with their partner and young child.

  127. 127

    My experience starting TRT using gel ↗

    Community account

    Public thread reviewed: opening post and 4 comments.

    Detail: A man in his 50s reports rapid improvements in energy, clarity, and sex drive after starting AndroGel for lethargy and low libido.

  128. 128

    Gel spiked my HCT to 50%. Doc suggests 3-month depot shot. Is this a recipe for disaster? ↗

    Community account

    Public thread reviewed: opening post and 16 comments.

    Detail: A man in his 30s stopped 50mg of Testogel daily after two months when hematocrit rose from 40% to 50% alongside fatigue and head pressure.

  129. 129

    30M, low T before short TRT and borderline labs after stopping Testogel 7/8 Months ago. ↗

    Community account

    Public thread reviewed: opening post and 3 comments.

    Detail: A man in his 30s received Testogel from his GP after a low testosterone result, then stopped after several months because of hair loss, testicular shrinkage, and doubts about the care he was receiving.

  130. 130

    Switching from gel to pins ↗

    Community account

    Public thread reviewed: opening post and 3 comments.

    Detail: The OP said gel improved symptoms for four to eight hours, then left them feeling low and without energy.

  131. 131

    AndroGel starting dosage of 100mg/day - is it OK? ↗

    Community account

    Public thread reviewed: opening post and 11 comments.

    Detail: A man starting TRT questioned a clinic's prescription of AndroGel 1% at 100 mg daily because he expected a lower starting dose.

  132. 132

    Starting TRT gel after running on empty basically my whole life — anyone else on gel? ↗

    Community account

    Public thread reviewed: opening post and 10 comments.

    Detail: The poster had planned two pumps of testosterone gel each morning after very low testosterone readings and a long history of symptoms.

  133. 133

    How long until T gel impacts husband? ↗

    Community account

    Public thread reviewed: opening post and 23 comments.

    Detail: The poster asked when her husband's 1.62 testosterone gel might improve erections after about two weeks of use.

  134. 134

    15 months on Testogel (4 pumps/day) – Seeking advice on absorption & splitting dose to inner thighs? ↗

    Community account

    Public thread reviewed: opening post and 15 comments.

    Detail: After 15 months on Testogel, the poster felt his latest testosterone result was lower than expected for four pumps each morning and reported daytime energy fluctuations.

  135. 135

    Very low testosterone - GP will only prescribes gel ↗

    Community account

    Public thread reviewed: opening post and 12 comments.

    Detail: A man in his 50s with very low testosterone used prescribed gel for six weeks after a GP offered that form of treatment.

  136. 136

    Swapped from 50mg androgel to 100mg cypionate IM few days ago and feel worse so far, normal? ↗

    Community account

    Public thread reviewed: opening post and 4 comments.

    Detail: A man in his 30s changed from years of 50 mg testosterone gel to an intramuscular cypionate injection.

  137. 137

    Wife's Testogel 50mg ↗

    Community account

    Public thread reviewed: opening post and 41 comments.

    Detail: A man in his 40s with multiple sclerosis considered using his wife's Testogel 50mg for an extra gym boost despite describing his testosterone level as normal.

  138. 138

    DEPO-Testosterone (testosterone cypionate) injection, USP CIII ↗

    Product label (US)

    Full label reviewed.

    Detail: 50–400 mg every 2–4 weeks by intramuscular injection.

  139. 139

    XYOSTED (testosterone enanthate) injection, for subcutaneous use ↗

    Product label (US)

    Full label reviewed.

    Detail: 75 mg once weekly by subcutaneous autoinjector.

  140. 140

    AVEED (testosterone undecanoate) injection ↗

    Product label (US)

    Full label reviewed.

    Detail: 750 mg at start, at 4 weeks, then every 10 weeks; boxed warning for oil microembolism and anaphylaxis.

  141. 141

    KYZATREX (testosterone undecanoate) capsules ↗

    Product label (US)

    Full label reviewed.

    Detail: Starts at 200 mg twice daily with food; carries the TRAVERSE rhythm, kidney and clot results.

  142. 142

    NATESTO (testosterone) nasal gel ↗

    Product label (US)

    Full label reviewed.

    Detail: 11 mg per dose (one 5.5 mg spray in each nostril), three times daily; no boxed warning on secondary exposure.

  143. 143

    TESTOPEL (testosterone pellets) for subcutaneous implantation ↗

    Product label (US)

    Full label reviewed.

    Detail: 150–450 mg (two to six 75 mg pellets) every 3 to 6 months.

Updates and corrections

Updated September 28, 2026. This version replaces the earlier AndroGel, Testim, Fortesta, topical testosterone, Androderm and Striant guides with one rewrite based on current US, UK, Canadian and Australian labels and current clinical guidelines. It adds a protocol table with each schedule's source, the disagreement over when to draw blood on gel, application sites and washing waits by product, the transfer studies, storage, the full TRAVERSE results, what labels and guidelines ask prescribers to monitor, what happens when gel stops, a comparison with other forms and a dated legal-status summary. It corrects the earlier pages on several points: AndroGel 1% needs a 5-hour wait before showering, not 2; Fortesta and its generic are no longer sold in the US; Fortesta was adjusted by a level drawn 2 hours after application, not a trough; sunscreen and moisturizer slightly increase absorption rather than interfering; gel results depend on when blood is drawn and from which arm; TRAVERSE's safety margin was 1.5; UK Testogel is now 16.2 mg/g; and the label contraindications are breast cancer, known or suspected prostate cancer and pregnancy. The date describes this revision, not a fresh check of every source.

Found an error or a relevant study we missed? Report a correction with the guide title, the specific passage and a supporting source if available. Please leave out personal health records. See our editorial policy for how we handle attribution, evidence limits and corrections.